Rules of
Department of Health
Division 30—Division of Health Standards and Licensure
Chapter 1—Controlled Substances

Title | Page
--- | ---
19 CSR 30-1.002 | Schedules of Controlled Substances .........................................................3
19 CSR 30-1.004 | List of Excepted Substances ..................................................................8
19 CSR 30-1.006 | List of Exempt Anabolic Steroid Products .................................................8
19 CSR 30-1.008 | List of Excluded Veterinary Anabolic Steroid Implant Products ...............9
19 CSR 30-1.010 | Schedules of Controlled Substances (Rescinded November 30, 2000) ........9
19 CSR 30-1.011 | Definitions..........................................................................................10
19 CSR 30-1.013 | Miscellaneous Fees .............................................................................10
19 CSR 30-1.015 | Registration Fees and Implementation of Three-Year Cycle ....................11
19 CSR 30-1.017 | Registration Process ............................................................................11
19 CSR 30-1.019 | Registration Location .........................................................................16
19 CSR 30-1.020 | List of Excepted Substances (Rescinded November 30, 2000) ................16
19 CSR 30-1.023 | Registration Changes ............................................................................16
19 CSR 30-1.025 | List of Exempt Anabolic Steroid Products (Rescinded November 30, 2000) 16
19 CSR 30-1.026 | Separate Registration ...........................................................................16
19 CSR 30-1.027 | Investigative and Administrative Procedures .........................................17
19 CSR 30-1.030 | Requirements for Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................17
19 CSR 30-1.031 | Physical Security Requirements .................................................................17
19 CSR 30-1.032 | Security for Nonpractitioners .................................................................18
19 CSR 30-1.033 | Hearing Procedures on Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................18
19 CSR 30-1.034 | Security for Practitioners ......................................................................18
<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 CSR 30-1.035</td>
<td>Requirements for Prescribing, Dispensing and Administering Controlled Substances (Rescinded November 30, 2000)</td>
</tr>
<tr>
<td>19 CSR 30-1.036</td>
<td>Disposing of Unwanted Controlled Substances (Rescinded November 30, 2000)</td>
</tr>
<tr>
<td>19 CSR 30-1.040</td>
<td>Dispensing and Distribution of Controlled Substances in Certain Situations</td>
</tr>
<tr>
<td>19 CSR 30-1.041</td>
<td>Records Requirements</td>
</tr>
<tr>
<td>19 CSR 30-1.042</td>
<td>Inventory Requirements</td>
</tr>
<tr>
<td>19 CSR 30-1.044</td>
<td>Continuing Records General Requirements</td>
</tr>
<tr>
<td>19 CSR 30-1.046</td>
<td>Records for Manufacturers, Distributors, Importers and Exporters</td>
</tr>
<tr>
<td>19 CSR 30-1.048</td>
<td>Records for Practitioners and Researchers</td>
</tr>
<tr>
<td>19 CSR 30-1.050</td>
<td>Records for Chemical Analysts</td>
</tr>
<tr>
<td>19 CSR 30-1.052</td>
<td>Records for Long-Term Care Facilities (LTCF)</td>
</tr>
<tr>
<td>19 CSR 30-1.060</td>
<td>Determining Lawful Prescribing, Dispensing and Administering of Controlled Substances</td>
</tr>
<tr>
<td>19 CSR 30-1.062</td>
<td>Transmission of Prescriptions</td>
</tr>
<tr>
<td>19 CSR 30-1.064</td>
<td>Partial Filling of Schedule II Prescriptions</td>
</tr>
<tr>
<td>19 CSR 30-1.066</td>
<td>Dispensing by Individual Practitioners</td>
</tr>
<tr>
<td>19 CSR 30-1.068</td>
<td>Administering In Emergency Rooms</td>
</tr>
<tr>
<td>19 CSR 30-1.070</td>
<td>Emergency Dispensing of Schedule II Substances</td>
</tr>
<tr>
<td>19 CSR 30-1.072</td>
<td>Dispensing of Schedule V Substances</td>
</tr>
<tr>
<td>19 CSR 30-1.074</td>
<td>Dispensing Without a Prescription</td>
</tr>
<tr>
<td>19 CSR 30-1.076</td>
<td>Emergency Distribution by a Pharmacy</td>
</tr>
<tr>
<td>19 CSR 30-1.078</td>
<td>Disposing of Unwanted Controlled Substances</td>
</tr>
</tbody>
</table>
### Title 19—DEPARTMENT OF HEALTH
#### Division 30—Division of Health Standards and Licensure

#### Chapter 1—Controlled Substances

##### 19 CSR 30-1.002 Schedules of Controlled Substances

**PURPOSE:** Chapter 195, RSMo states in section 195.230, RSMo that the Department of Health shall prepare a list of all drugs falling within the purview of controlled substances. Upon preparation, a copy of the list shall be filed in the Office of the Secretary of State. It also requires, in section 195.017.11, RSMo, the Department of Health to revise and republish the schedules semiannually for two years from September 28, 1971, and annually after that.

(1) Schedules of Controlled Substances.

(A) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the Drug Enforcement Administration (DEA) Controlled Substances Code Number set forth opposite it.

1. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers and salts, isomers and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:

<table>
<thead>
<tr>
<th>Code No.</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>9815</td>
<td>Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide)</td>
</tr>
<tr>
<td>9601</td>
<td>Acetylmethadol</td>
</tr>
<tr>
<td>9602</td>
<td>Allylprodine</td>
</tr>
<tr>
<td>9813</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9611</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9612</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9613</td>
<td>Diapipane</td>
</tr>
<tr>
<td>9622</td>
<td>Dextromoramide</td>
</tr>
<tr>
<td>9623</td>
<td>Ethylmethylthiambutene</td>
</tr>
<tr>
<td>9624</td>
<td>Etonizatene</td>
</tr>
<tr>
<td>9625</td>
<td>Etoxeridine</td>
</tr>
<tr>
<td>9626</td>
<td>Furethidine</td>
</tr>
<tr>
<td>9627</td>
<td>Hydroxypethidine</td>
</tr>
<tr>
<td>9628</td>
<td>Ketobemidone</td>
</tr>
<tr>
<td>9629</td>
<td>Levomoramide</td>
</tr>
<tr>
<td>9630</td>
<td>Mephenesacyclorphan</td>
</tr>
<tr>
<td>9631</td>
<td>Methylfentanyl (N-(3-methyl-1-(2-phenoxyethyl)-4-piperidinyl)-N-phenylpropanamide), its optical and geometric isomers, salts and salts of isomers</td>
</tr>
<tr>
<td>9632</td>
<td>Morphine</td>
</tr>
<tr>
<td>9633</td>
<td>Morphenamine</td>
</tr>
<tr>
<td>9634</td>
<td>Nicocodeine</td>
</tr>
<tr>
<td>9635</td>
<td>Nicomorphine</td>
</tr>
<tr>
<td>9636</td>
<td>Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide</td>
</tr>
<tr>
<td>9833</td>
<td>Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide)</td>
</tr>
<tr>
<td>9831</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9608</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9609</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9611</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9612</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9613</td>
<td>Diapipane</td>
</tr>
<tr>
<td>9622</td>
<td>Dextromoramide</td>
</tr>
<tr>
<td>9623</td>
<td>Ethylmethylthiambutene</td>
</tr>
<tr>
<td>9624</td>
<td>Etonizatene</td>
</tr>
<tr>
<td>9625</td>
<td>Etoxeridine</td>
</tr>
<tr>
<td>9626</td>
<td>Furethidine</td>
</tr>
<tr>
<td>9627</td>
<td>Hydroxypethidine</td>
</tr>
<tr>
<td>9628</td>
<td>Ketobemidone</td>
</tr>
<tr>
<td>9629</td>
<td>Levomoramide</td>
</tr>
<tr>
<td>9630</td>
<td>Mephenesacyclorphan</td>
</tr>
<tr>
<td>9631</td>
<td>Methylfentanyl (N-(3-methyl-1-(2-phenoxyethyl)-4-piperidinyl)-N-phenylpropanamide), its optical and geometric isomers, salts and salts of isomers</td>
</tr>
<tr>
<td>9632</td>
<td>Morphine</td>
</tr>
<tr>
<td>9633</td>
<td>Morphenamine</td>
</tr>
<tr>
<td>9634</td>
<td>Nicocodeine</td>
</tr>
<tr>
<td>9635</td>
<td>Nicomorphine</td>
</tr>
<tr>
<td>9636</td>
<td>Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide</td>
</tr>
<tr>
<td>9833</td>
<td>Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide)</td>
</tr>
<tr>
<td>9831</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9608</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9609</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9611</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9612</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9613</td>
<td>Diapipane</td>
</tr>
<tr>
<td>9622</td>
<td>Dextromoramide</td>
</tr>
<tr>
<td>9623</td>
<td>Ethylmethylthiambutene</td>
</tr>
<tr>
<td>9624</td>
<td>Etonizatene</td>
</tr>
<tr>
<td>9625</td>
<td>Etoxeridine</td>
</tr>
<tr>
<td>9626</td>
<td>Furethidine</td>
</tr>
<tr>
<td>9627</td>
<td>Hydroxypethidine</td>
</tr>
<tr>
<td>9628</td>
<td>Ketobemidone</td>
</tr>
<tr>
<td>9629</td>
<td>Levomoramide</td>
</tr>
<tr>
<td>9630</td>
<td>Mephenesacyclorphan</td>
</tr>
<tr>
<td>9631</td>
<td>Methylfentanyl (N-(3-methyl-1-(2-phenoxyethyl)-4-piperidinyl)-N-phenylpropanamide), its optical and geometric isomers, salts and salts of isomers</td>
</tr>
<tr>
<td>9632</td>
<td>Morphine</td>
</tr>
<tr>
<td>9633</td>
<td>Morphenamine</td>
</tr>
<tr>
<td>9634</td>
<td>Nicocodeine</td>
</tr>
<tr>
<td>9635</td>
<td>Nicomorphine</td>
</tr>
<tr>
<td>9636</td>
<td>Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide</td>
</tr>
<tr>
<td>9831</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9608</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9609</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9611</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9612</td>
<td>Betamethadon</td>
</tr>
<tr>
<td>9613</td>
<td>Diapipane</td>
</tr>
<tr>
<td>9622</td>
<td>Dextromoramide</td>
</tr>
<tr>
<td>9623</td>
<td>Ethylmethylthiambutene</td>
</tr>
<tr>
<td>9624</td>
<td>Etonizatene</td>
</tr>
<tr>
<td>9625</td>
<td>Etoxeridine</td>
</tr>
<tr>
<td>9626</td>
<td>Furethidine</td>
</tr>
<tr>
<td>9627</td>
<td>Hydroxypethidine</td>
</tr>
<tr>
<td>9628</td>
<td>Ketobemidone</td>
</tr>
<tr>
<td>9629</td>
<td>Levomoramide</td>
</tr>
<tr>
<td>9630</td>
<td>Mephenesacyclorphan</td>
</tr>
<tr>
<td>9631</td>
<td>Methylfentanyl (N-(3-methyl-1-(2-phenoxyethyl)-4-piperidinyl)-N-phenylpropanamide), its optical and geometric isomers, salts and salts of isomers</td>
</tr>
<tr>
<td>9632</td>
<td>Morphine</td>
</tr>
<tr>
<td>9633</td>
<td>Morphenamine</td>
</tr>
<tr>
<td>9634</td>
<td>Nicocodeine</td>
</tr>
<tr>
<td>9635</td>
<td>Nicomorphine</td>
</tr>
<tr>
<td>9636</td>
<td>Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide</td>
</tr>
</tbody>
</table>

2. Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

<table>
<thead>
<tr>
<th>Code No.</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>9051</td>
<td>Acetylidiocodine</td>
</tr>
<tr>
<td>9052</td>
<td>Benzylmorphine</td>
</tr>
<tr>
<td>9070</td>
<td>Codeine methylbromide</td>
</tr>
<tr>
<td>9053</td>
<td>Codeine-N-Oxide</td>
</tr>
<tr>
<td>9054</td>
<td>Cyprenorphine</td>
</tr>
<tr>
<td>9055</td>
<td>Deoxynorcodeine</td>
</tr>
<tr>
<td>9145</td>
<td>Dihydromorphone</td>
</tr>
<tr>
<td>9335</td>
<td>Drotebanol</td>
</tr>
<tr>
<td>9056</td>
<td>Etorphine (except hydrochloride salt)</td>
</tr>
<tr>
<td>9200</td>
<td>Heroin</td>
</tr>
<tr>
<td>9301</td>
<td>Hydromorphan</td>
</tr>
<tr>
<td>9302</td>
<td>Methyldesorphone</td>
</tr>
<tr>
<td>9304</td>
<td>Methylidihydmorphone</td>
</tr>
<tr>
<td>9305</td>
<td>Morphine methylbromide</td>
</tr>
<tr>
<td>9306</td>
<td>Morphine methylsulfonate</td>
</tr>
<tr>
<td>9307</td>
<td>Morphine-N-Oxide</td>
</tr>
<tr>
<td>9308</td>
<td>Myrophine</td>
</tr>
<tr>
<td>9309</td>
<td>Nicocodeine</td>
</tr>
<tr>
<td>9312</td>
<td>Nicomorphine</td>
</tr>
<tr>
<td>9313</td>
<td>Normorphine</td>
</tr>
<tr>
<td>9314</td>
<td>Pholcodeine</td>
</tr>
<tr>
<td>9315</td>
<td>Thebacon</td>
</tr>
<tr>
<td>7391</td>
<td>Alpha-ethyltryptamine</td>
</tr>
<tr>
<td>7392</td>
<td>Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET and AET;</td>
</tr>
<tr>
<td>7391</td>
<td>Some trade or other names: 4-bromo-2,5-dimethoxyamphetamine; alpha-ET and AET;</td>
</tr>
<tr>
<td>7392</td>
<td>Some trade or other names: 4-bromo-2,5-dimethoxyamphetamine; alpha-ET and AET;</td>
</tr>
<tr>
<td>7391</td>
<td>Some trade or other names: 4-bromo-2,5-dimethoxyamphetamine; alpha-ET and AET;</td>
</tr>
</tbody>
</table>
D. 2,5-dimethoxyamphetamine 7396
Some trade or other names: 2,5-dimethoxy-N,N-dimethylphenethylamine; 2,5-DMA;
E. 2,5-dimethoxy-4-ethylampheta-
mine 7399
(Some trade or other names: DOET)
F. 4-methoxyamphetamine 7411
Some trade or other names: 4-methoxy-N,N-dimethylphenethylamine; paramethoxy-
amphetamine; PMA;
G. 5-methoxy-3,4-methylenedioxy-
amphetamine 7401
H. 4-methyl-2,5-dimethoxyamphet-
amine 7395
Some trade and other names: 4-methyl-2,5-
dimethoxy-N-methylphenethylamine; DOM; and STP;
I. 3,4-methylenedioxymorphine 7400
Some trade and other names: 3-(b-
Dimethylaminophenethyl)-5-hydroxyindo-; 3-(2-
dimethylaminophenethyl)-5-indolol; N; N-
dimethylserotonin; 5-hydroxy-N,N-dimethyl-
tryptamine; mappine;
O. Diethyltryptamine 7434
Some trade and other names: N; N-
Diethyltryptamine; DET;
P. Dimethyltryptamine 7435
Some trade or other names: DMT;
Q. Iboigaine 7260
Some trade and other names: 7-Ethyl-
6,6b,7,8,9,10,12,13-octahydro-2-methoxy-6, 
9-methano-5H-pyrido (1',2':1,2) azepon (5, 
4-b) indole; Tabernanthe iboga;
R. Lysergic acid diethylamide 7315
S. Maribuxam 7360
Some trade or other names: marijuana;
T. Mescaline 7381
U. Parahexyl 7374
Some trade or other names: 3-Hexyl-1-
Hydroxy-7,8,9,10-tetrahydro-6,6,9-
trimethyl-6H-dibenzo(b,d)pyran; Synhexyl;
V. Peyote 7415
Meaning all parts of the plant presently clas-
sified botanically as Lophophora williamsil 
Lemaire, whether growing or not; the seeds 
thereof; any extract from any part of such 
plant; and every compound, manufacture, 
salt, derivative, mixture or preparation of 
such plant, its seeds or extracts;
W. N-ethyl-3-piperidyl benz-
late 7482
X. N-methyl-3-piperidyl benz-
late 7484
Y. Psilocybin 7437
Z. Psilocyn 7438
AA. Tetrahycannabionols 7370
Synthetic equivalents of the substances con-
tained in the plant or in the resinous ex-
tractives of Cannabis, sp, synthetic substances, 
derivatives and their isomers, or both, with 
similar chemical structure and pharmacolog-
ical activity such as the following:
(I) D 1 cis or trans tetrahydro-
cannabinol and their optical isomers;
(II) D 6 cis or trans tetrahydro-
cannabinol and their optical isomers; and
(III) D 3, 4 cis or trans tetrahydro-
cannabinol and its optical isomers (Since 
nomenclature of these substances is not inter-
nationally standardized, compounds of these 
structures, regardless of numerical designa-
tion of atomic positions are covered);
BB. Ethylamine analog of phenycycl-
dine 7455
Some trade or other names: N-ethyl-
phenylcyclohexylamine, (1-phenylcyclo-
hexyl) ethylamine, (1-phenylcyclohexyl)-ethy-
lamine, cyclohexamine, PCE;
CC. Pyrrolidine analog of phenycycl-
dine 7458
Some trade or other names: 1(1-phenylcy-
hol)pyrrolidine PCPy, PHP;
DD. Thiophene analog of phenycycl-
dine 7470
Some trade or other names: 1-(1-thiency-
hexyl)pyrrolidine (benzyl-
thenylfentanyl), its optical 
isomers, salts and salts of optical isomers 9834
4. Depressants. Unless specifically 
excepted or unless listed in another schedule, any 
material compound, mixture or prepara-
tion which contains any quantity of the fol-
lowing substances having a depressant effect 
on the central nervous system, including its 
salts, isomers and salts of isomers:
A. Aminorex; 1585
Some trade or other names: aminoxaphen; 2-
amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-
phenyl-2-oxazolamine;
B. Cathinone (Some trade or other 
names: 2-amino-1-phenyl-1-
propanone, alphaamino-
propiophenone, 2-amino propi-
ophenone and norephedrine) 1235
C. Fenethylline 1503
D. Methcathinone 1585
Some trade or other names: 2-(methyl-
aminopropiophenone; alpha-(methyl-
aminopropiophenone; 2-(methylamino)-1-
phenylpropan-1-one; alpha-N-methylamino-
propio phenone; monomethylpropion; eph-
дрено; N-methylcathinone; methylcathinone; 
AL-464; AL-422; AL-463 and URI 432; its 
salts, optical isomers and salts of optical isomers;
E. (±)cis-4-methylaminorex ((±)cis-
4,5-dihydro-4-methyl-5-phenyl-2-
oxazoline) 1590
F. N-ethylamphetamine 1475
G. N,N-dimethylamphetamine 1480
(some other names: N,N-alpha-trimethyl-
benzene ethanamine; N,N-alpha-trimethyl-
phenethylamine), its salts, optical isomers and salts of optical isomers.
6. A temporary listing of substances subject to 
emergency scheduling under federal 
law shall include any material, compound, 
mixture or preparation which contains any 
quantity of the following substances:
A. N-(1-benzyl-4-piperidyl)-N-phe-
ymethylpropanamide (benzyl-
fentanyl), its optical isomers, salts and salts of isomers 9818
B. N-(1-(2-thienyl) methyl-4-piper-
idyl)-N-phenylpropanamide (thienylfentanyl), its optical 
salts, isomers and salts of isomers 9834
(B) Schedule II shall consist of the drugs and 
other substances, by whatever official 
name, common or usual name, chemical 
name or brand name designated, listed in this 
section. Each drug or substance has been 
assigned the Controlled Substances Code 
Number set forth opposite it.
of opium or opiate, excluding apomorphine, thebaine-devied butorphanol, dextrophan, nalbuphine, nalmefine, naloxone and nal-trexone and their respective salts, but including the following:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw opium</td>
<td>9600</td>
</tr>
<tr>
<td>Opium extracts</td>
<td>9610</td>
</tr>
<tr>
<td>Opium fluid</td>
<td>9620</td>
</tr>
<tr>
<td>Powdered opium</td>
<td>9639</td>
</tr>
<tr>
<td>Granulated opium</td>
<td>9640</td>
</tr>
<tr>
<td>Tincture of opium</td>
<td>9650</td>
</tr>
<tr>
<td>Cokeine</td>
<td>9050</td>
</tr>
<tr>
<td>Ethylmorphine</td>
<td>9190</td>
</tr>
<tr>
<td>Etorphine hydrochloride</td>
<td>9059</td>
</tr>
<tr>
<td>Hydrocgonone</td>
<td>9193</td>
</tr>
<tr>
<td>Hydromorph particulate</td>
<td>9150</td>
</tr>
<tr>
<td>Metopon</td>
<td>9250</td>
</tr>
<tr>
<td>Morphine</td>
<td>9300</td>
</tr>
<tr>
<td>Oxycodeine</td>
<td>9143</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>9652</td>
</tr>
<tr>
<td>Thebaine</td>
<td>9333</td>
</tr>
</tbody>
</table>

Any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1)(B)1. of this rule shall be included in Schedule II, except that these substances shall not include the isosolinoine alkaloids of opium; opium poppy and poppy straw; coca leaves and coca leaves and their salts, isomers, derivatives and salts of isomers and derivatives and any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine and concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid and powder form which contains the phenanthrene alkaloids of the poppy poppy) 9670.

2. Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation, dextrophan and levopropoxyphene excepted:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfentanil</td>
<td>9737</td>
</tr>
<tr>
<td>Alphaprodine</td>
<td>9010</td>
</tr>
<tr>
<td>Anileridine</td>
<td>9020</td>
</tr>
<tr>
<td>Betzimamide</td>
<td>9800</td>
</tr>
<tr>
<td>Bulk Dextropoxyphene (Non-dosage Forms)</td>
<td>9273</td>
</tr>
<tr>
<td>Butyl-nitrite no designated number</td>
<td></td>
</tr>
<tr>
<td>G. Carfentanil</td>
<td>9743</td>
</tr>
<tr>
<td>H. Dihydrocodeine</td>
<td>9120</td>
</tr>
<tr>
<td>I. Diphenoxylate</td>
<td>9170</td>
</tr>
<tr>
<td>J. Fentanyl</td>
<td>9801</td>
</tr>
<tr>
<td>K. Isomethadone</td>
<td>9226</td>
</tr>
<tr>
<td>L. Levo-alphaethylmethadol</td>
<td>9220</td>
</tr>
<tr>
<td>M. Levomethadyl acetate, LAAM</td>
<td>9648</td>
</tr>
<tr>
<td>N. Levorphanol</td>
<td>9220</td>
</tr>
<tr>
<td>O. Metazocine</td>
<td>9240</td>
</tr>
<tr>
<td>P. Methadone</td>
<td>9250</td>
</tr>
<tr>
<td>Q. Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butanone</td>
<td>9254</td>
</tr>
<tr>
<td>R. Moramide-Intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid</td>
<td>9802</td>
</tr>
<tr>
<td>S. Pethidine (Meperidine)</td>
<td>9230</td>
</tr>
<tr>
<td>T. Pethidine-Intermediate-A, 4-cyanomethyl-4-phenylperipertidine</td>
<td>9232</td>
</tr>
<tr>
<td>U. Pethidine-Intermediate-B, ethyl-4-phenylperipertidine-4-carboxylate</td>
<td>9233</td>
</tr>
<tr>
<td>V. Pethidine-Intermediate-C, 1-methyl-4-phenylperipertidine-4-carboxylic acid</td>
<td>9234</td>
</tr>
<tr>
<td>W. Phenazocine</td>
<td>9715</td>
</tr>
<tr>
<td>X. Pinimidine</td>
<td>9730</td>
</tr>
<tr>
<td>Y. Racemethorphan</td>
<td>9732</td>
</tr>
<tr>
<td>Z. Racemorphon</td>
<td>9733</td>
</tr>
<tr>
<td>AA. Remifentanil</td>
<td>9739</td>
</tr>
<tr>
<td>BB. Sufentanil</td>
<td>9740</td>
</tr>
</tbody>
</table>

3. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine, its salts, optical isomers and salts of its optical isomers</td>
<td>1100</td>
</tr>
<tr>
<td>Methamphetamine, its salts, isomers and salts of its isomers</td>
<td>1105</td>
</tr>
<tr>
<td>Phenmetrazine and its salts</td>
<td>1631</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>1724</td>
</tr>
</tbody>
</table>

4. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amobarbital</td>
<td>2125</td>
</tr>
<tr>
<td>Butalbital</td>
<td>2250</td>
</tr>
<tr>
<td>Pentobarbital</td>
<td>2270</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>7471</td>
</tr>
<tr>
<td>Secobarbital</td>
<td>2315</td>
</tr>
</tbody>
</table>

5. Hallucinogenic substances:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Nabilone</td>
<td>7379</td>
</tr>
</tbody>
</table>

(Another name for nabilone: (±)trans-3-(1,1-dimethylheptyl)-6, 6a,7,8,10,10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo(b,d) pyran-9-one.)

6. Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances has a depressant effect on the central nervous system:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Immediate precursor to amphetamine and methamphetamine:</td>
<td></td>
</tr>
<tr>
<td>(I) Phenylacetone</td>
<td>8501</td>
</tr>
<tr>
<td>Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; benzyl methyl ketone;</td>
<td></td>
</tr>
<tr>
<td>B. Immediate precursors to phenyclyidine (PCP): (I) 1-phenylcyclohexylamine</td>
<td>7460</td>
</tr>
<tr>
<td>(II) 1-piperidinocyclohexane-carbonitrile (PCC)</td>
<td>8603</td>
</tr>
</tbody>
</table>

(C) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

1. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances has a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Those compounds, mixtures or preparations in dosage unit form containing</td>
<td></td>
</tr>
<tr>
<td>any stimulant substances listed in Schedule II which compounds, mixtures or preparations were listed on August 25, 1971, as excepted compounds under section 308.32 and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances</td>
<td>1330</td>
</tr>
<tr>
<td>B. Benzphetamine</td>
<td>1228</td>
</tr>
<tr>
<td>C. Chlordihaleteronelline</td>
<td>1645</td>
</tr>
<tr>
<td>D. Clortermine</td>
<td>1647</td>
</tr>
<tr>
<td>E. Phenimetrazine</td>
<td>1615</td>
</tr>
</tbody>
</table>

2. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances has a depressant effect on the central nervous system:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Any compound, mixture or preparation containing:</td>
<td></td>
</tr>
<tr>
<td>(I) Amobarbital</td>
<td>2126</td>
</tr>
</tbody>
</table>
B. Any suppository dosage form containing:

- (I) Amobarbital
- (II) Secobarbital
- (III) Pentobarbital

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

C. Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof

Some trade or other names for tiletamine: 2-

D. Chlorhexadol
E. Ketamine
F. Lysergic acid
G. Lysergic acid amide
H. Methyprylon
I. Sulfonmethane
J. Sulfonethylmethane
K. Sulfonmethane
L. Tiletamine and zolazepam

or any salt thereof

Some trade or other names for a tiletamine-zolazepam combination product: Telazol.

Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e) (1,4)-diazepin-7(1H)-one, flupyrazap.

3. Nalorphine

4. Narcotics drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

- A. Not more than 1.8 grams of codeine per one hundred milliliters (100 ml) or more than ninety milligrams (90 mg) per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium

- B. Not more than 1.8 grams of codeine per one hundred milliliters (100 ml) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts

- C. Not more than three hundred milligrams (300 mg) of hydrocodeine per one hundred milliliters (100 ml) or not more than fifteen milligrams (15 mg) per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium

- D. Not more than three hundred milligrams (300 mg) of hydrocodeine per one hundred milliliters (100 ml) or not more than fifteen milligrams (15 mg) per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts

E. Not more than 1.8 grams of dihydrocodeine per one hundred milliliters (100 ml) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts

F. Not more than three hundred milligrams (300 mg) of ethylmorphine per one hundred milliliters (100 ml) or not more than fifteen milligrams (15 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts

G. Not more than five hundred milligrams (500 mg) of opium per one hundred milliliters (100 ml) or per one hundred grams (100 g) or not more than twenty-five milligrams (25 mg) per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts

H. Not more than fifty milligrams (50 mg) of morphine per one hundred milliliters (100 ml) or per one hundred grams (100 g), with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts

5. Anabolic steroids. Unless specially excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, isomers and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation. DEA has assigned code 4000 for all anabolic steroids.

- A. Boldenone
- B. Chlorotestosterone (4-Chlorotestosterone)
- C. Clostebol
- D. Dehydrochloromethyltestosterone
- E. Dihydrotestosterone (4-Dihydrotestosterone)
- F. Drostanolone
- G. Ethylestrenol
- H. Fluoxymesterone
- I. Formebulone (Formebolone)
- J. Methadonene
- K. Methandranone
- L. Methandriol
- M. Methandrostenolone
- N. Methandronone
- O. Methenolone
- P. Mibolerone
- Q. Nandrolone
- R. Nandrolone
- S. Nordetranolone
- T. Oxandrolone
- U. Oxymesterone
- V. Oxymetholone
- W. Stanolone
- X. Stanozolol
- Y. Testolactone
- Z. Testosterone
- AA. Trenbolone

BB. Any salt, ester, or isomer of a drug or substance described or listed in this subparagraph, if that salt, ester or isomer promotes muscle growth except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the secretary of Health and Human Services for that administration.

6. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product

(Some other names for dronabinol: (6αR-trans)-6α,7,8,10a-tetrahydro-6.9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol, or (-) -delta-9-(trans)-tetrahydrocannabinol.)

(D) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

1. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

- A. Not more than one milligram (1 mg) of difenoxin (DEA Drug Code No. 9618) and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit;

- B. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) 9278

C. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

- (I) Not more than two hundred milligrams (200 mg) of codeine per one hundred milliliters (100 ml) or per one hundred grams (100 g);

- (II) Not more than one hundred milligrams (100 mg) of dihydrocodeine per one hundred milliliters (100 ml) or per one hundred grams (100 g); or
(III) Not more than one hundred milligrams (100 mg) of ethylmorphine per one hundred milliliters (100 ml) or per one hundred grams (100 g).

2. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

- A. Alprazolam 2882
- B. Barbital 2145
- C. Bromazepam 2748
- D. Camazepam 2749
- E. Chloral betaine 2460
- F. Chloral hydrate 2465
- G. Chloridiazepoxide 2744
- H. Clobazam 2751
- I. Clonazepam 2737
- J. Clorazepate 2768
- K. Clotiacepam 2752
- L. Cloxazolam 2753
- M. Delorazepam 2754
- N. Diazepam 2765
- O. Estazolam 2756
- P. Ethchlorvylnol 2540
- Q. Ethinamate 2545
- R. Ethyl loflazepate 2758
- S. Fludiazepam 2759
- T. Flunitrazepam 2763
- U. Flurazepam 2767
- V. Halazepam 2762
- W. Haloxazolam 2771
- X. Ketazolam 2772
- Y. Lorazepam 2773
- Z. Lorazepam 2885
- AA. Lormetazepam 2774
- BB. Mebutamate 2800
- CC. Medazepam 2836
- DD. Deprobarbital 2820
- EE. Methohexitol 2264
- FF. Methylphenobarbital (Mepho-barbital) 2250
- GG. Midazolam 2884
- HH. Nimetazepam 2837
- II. Nitrazepam 2834
- JJ. Nordiazepam 2838
- KK. Oxazepam 2838
- LL. Oxazolam 2839
- MM. Paraldehyde 2585
- NN. Petrichloral 2591
- OO. Phenobarbital 2285
- PP. Pinazepam 2883
- QQ. Prazepam 2764
- RR. Quazepam 2881
- SS. Temazepam 2925
- TT. Trazepam 2886
- UU. Triazolam 2887
- VV. Zaleplon 2781

2. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

- A. Buprenorphine 9064

(2) Excluded Nonnarcotic Substances. The following nonnarcotic substances which, under the Federal Food, Drug and Cosmetic Act (21 U.S.C. 301), may be lawfully sold over the counter without a prescription, are exempted from all schedules pursuant to section 195.015(5), RSMo.
19 CSR 30-1.004 List of Excepted Substances

PURPOSE: The Department of Health is authorized to except by rule any compound, mixture or preparation containing any stimulant or depressant substance if one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system is included to negate the potential for abuse. The compounds, mixtures and preparations excluded are listed in this rule.

PUBLISHER’S NOTE: The publication of the full text of the material that the adopting agency has incorporated by reference in this rule would be unduly cumbersome or expensive. Therefore, the full text of that material will be made available to any interested person at both the Office of the Secretary of State and the Office of the adopting agency, pursuant to section 536.031.4, RSMo. Such material will be provided at the cost established by state law.

(1) Excepted Stimulant or Depressant Compounds—Exempt Prescription Products. The listed drugs in dosage unit form and any other drug of the quantitative composition shown in Part 1300 to end of Title 21, the Code of Federal Regulations, April 1998 or which is the same except that it contains a lesser quantity of controlled substances or other substances which do not have a stimulant, depressant or hallucinogenic effect and which are restricted by law to dispensing or prescription, are excepted from the provisions of sections 195.030, 195.040, 195.050 and 195.100, RSMo as provided for in section 195.017.6(5) and .8(3), RSMo. The rules of the Drug Enforcement Administration, 21 CFR Part 1300 to the end of Title 21, are hereby incorporated by reference and made a part of this rule.

(2) Excepted Chemical Preparations—Exempt Chemical Preparations. The listed preparations in unit form and any other preparation of the quantitative composition shown in Part 1300 to end of Title 21, the Code of Federal Regulations, April 1998 or which is the same except that it contains a lesser quantity of controlled substances or other substances which do not have a stimulant, depressant or hallucinogenic effect are excepted from the provisions of sections 195.030, 195.040, 195.050 and 195.110, RSMo as provided for in section 195.017.6(5) and .8(3), RSMo. The rules of the Drug Enforcement Administration, 21 CFR Part 1300 to the end of Title 21, are hereby incorporated by reference and made a part of this rule.


19 CSR 30-1.006 List of Exempt Anabolic Steroid Products

PURPOSE: This rule maintains a list of anabolic steroid products excluded from 19 CSR 30-1.002(1)(C)5. in conformance with federal law.

(1) Persons who in the course of legitimate business handle products listed in the Table of Exempt Anabolic Steroid Products in this section shall be exempt from the registration, records, reports, prescriptions, physical security and import and export requirements associated with Schedule III substances.

Excluded Nonnarcotic Products

<table>
<thead>
<tr>
<th>Company</th>
<th>Trade Name</th>
<th>NDC Code</th>
<th>Form</th>
<th>Controlled Substance</th>
<th>mg or mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioline Laboratories</td>
<td>Theophed</td>
<td>00719-1945</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Goldline Laboratories</td>
<td>Guiaphed Elixir</td>
<td>00182-1377</td>
<td>EL</td>
<td>Phenobarbital</td>
<td>4.00</td>
</tr>
<tr>
<td>Goldline Laboratories</td>
<td>Tredigen Tablets</td>
<td>00182-0134</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Hawthorne Products, Inc.</td>
<td>Chota’s Leg Freeze</td>
<td>00071-0230</td>
<td>TB</td>
<td>Chloral hydrate</td>
<td>246.67</td>
</tr>
<tr>
<td>Parke-Davis &amp; Co.</td>
<td>Tedral</td>
<td>00071-0230</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Parke-Davis &amp; Co.</td>
<td>Tedral Elixir</td>
<td>00071-0242</td>
<td>EX</td>
<td>Phenobarbital</td>
<td>40.00</td>
</tr>
<tr>
<td>Parke-Davis &amp; Co.</td>
<td>Tedral S.A.</td>
<td>00071-0231</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Parke-Davis &amp; Co.</td>
<td>Tedral Suspension</td>
<td>00071-0237</td>
<td>SU</td>
<td>Phenobarbital</td>
<td>80.00</td>
</tr>
<tr>
<td>Parmed Pharmacy</td>
<td>Asma-Ese</td>
<td>00349-2018</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.10</td>
</tr>
<tr>
<td>Rondex Labs</td>
<td>Azma-Aids</td>
<td>00367-3153</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Smith Kline Consumer</td>
<td>Benzedrex</td>
<td>49692-0928</td>
<td>IN</td>
<td>Propylhexedrine</td>
<td>250.00</td>
</tr>
<tr>
<td>Sterling Drug, Inc.</td>
<td>Bronkoxilir</td>
<td>00057-1004</td>
<td>EL</td>
<td>Phenobarbital</td>
<td>0.80</td>
</tr>
<tr>
<td>Sterling Drug, Inc.</td>
<td>Bronkotabs</td>
<td>00057-1005</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
<tr>
<td>Vicks Chemical Co.</td>
<td>Vicks Inhaler</td>
<td>23900-0010</td>
<td>IN</td>
<td>I-Desoxyephedrine</td>
<td>113.00</td>
</tr>
<tr>
<td>White Hall Labs</td>
<td>Primatene (P-tablets)</td>
<td>00573-2940</td>
<td>TB</td>
<td>Phenobarbital</td>
<td>8.00</td>
</tr>
</tbody>
</table>

19 CSR 30-1.010 List of Exempt Anabolic Steroid Products

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Company</th>
<th>NDC or DIN No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgyn L.A.</td>
<td>Forest Pharmaceuticals,</td>
<td>0456-1005</td>
</tr>
<tr>
<td>Andro-Estro</td>
<td>Rugby Laboratories,</td>
<td>0536-1605</td>
</tr>
<tr>
<td>depANDROGYN</td>
<td>Forest Pharmaceuticals,</td>
<td>0456-1020</td>
</tr>
<tr>
<td>DEPO-T.E.</td>
<td>Quality Research Pharmaceuticals, Carnegie, IN</td>
<td>52765-257</td>
</tr>
<tr>
<td>depTESTROGEN</td>
<td>Marita Pharmaceuticals,</td>
<td>51698-257</td>
</tr>
<tr>
<td>Duomone</td>
<td>Winter Pharmaceuticals,</td>
<td>52047-360</td>
</tr>
<tr>
<td>DUO-SPAN II</td>
<td>Primedics Laboratories,</td>
<td>0684-0102</td>
</tr>
<tr>
<td>Estratest</td>
<td>Solvay Pharmaceuticals,</td>
<td>0032-1026</td>
</tr>
<tr>
<td>Estratest HS</td>
<td>Solvay Pharmaceuticals,</td>
<td>0032-1023</td>
</tr>
<tr>
<td>Menogen</td>
<td>Sage Pharmaceuticals,</td>
<td>59243-570</td>
</tr>
<tr>
<td>Menogen HS</td>
<td>Sage Pharmaceuticals,</td>
<td>59243-560</td>
</tr>
<tr>
<td>PAN ESTRA TEST</td>
<td>Pan American Labs,</td>
<td>0525-0175</td>
</tr>
<tr>
<td>Premarin with Methyldosterone</td>
<td>Ayerst Labs., Inc.</td>
<td>0046-0879</td>
</tr>
<tr>
<td>Premarin with Methyldosterone</td>
<td>Ayerst Labs., Inc.</td>
<td>0046-0878</td>
</tr>
<tr>
<td>Premarin with Methyldosterone</td>
<td>New York, NY</td>
<td>0046-0878</td>
</tr>
</tbody>
</table>

**19 CSR 30-1.008 List of Excluded Veterinary Anabolic Steroid Implant Products**

**PURPOSE:** This rule maintains a list of veterinary anabolic steroid products excluded from 19 CSR 30-1.002(1)(C)5. in conformance with federal law.

(1) The following products containing an anabolic steroid that are expressly intended for administration through implants to cattle or other nonhuman species and which have been approved by the Secretary of Health and Human Services for such administration and are excluded from all schedules pursuant to section 195.017.5, RSMo.

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Company</th>
<th>NDC or DIN No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Component E-H</td>
<td>Vetalife, Inc.</td>
<td>021641-002</td>
</tr>
<tr>
<td>(B) Component E-H</td>
<td>Norcross, GA</td>
<td>01968327</td>
</tr>
<tr>
<td>(C) Component TE-S</td>
<td>Vetalife, Inc.</td>
<td>021641-004</td>
</tr>
<tr>
<td>(D) Component T-H</td>
<td>Norcross, GA</td>
<td>021641-006</td>
</tr>
<tr>
<td>(E) Component T-S</td>
<td>Norcross, GA</td>
<td>021641-005</td>
</tr>
<tr>
<td>(F) F-TD</td>
<td>Animal Health,</td>
<td>00093351</td>
</tr>
<tr>
<td>(G) Finaplix-H</td>
<td>Hoechst Roussel Vet</td>
<td>12799-807-10</td>
</tr>
<tr>
<td>(H) Finaplix-S</td>
<td>Hoechst Roussel Vet</td>
<td>12799-807-07</td>
</tr>
<tr>
<td>(I) Heifer-oid</td>
<td>Boehringer Ingelheim</td>
<td>00894053</td>
</tr>
<tr>
<td>(J) Heifer-oid</td>
<td>Boehringer Ingelheim</td>
<td>00094053</td>
</tr>
<tr>
<td>(K) Heifer-oid</td>
<td>Ivory Laboratories, Inc.,</td>
<td></td>
</tr>
<tr>
<td>(L) Implus-H</td>
<td>Hoechst Roussel Vet</td>
<td>12799-811</td>
</tr>
<tr>
<td>(M) Implus-H</td>
<td>Hoechst Roussel Vet</td>
<td>12799-810</td>
</tr>
<tr>
<td>(N) Revalor-G</td>
<td>Hoechst Roussel Vet</td>
<td>0856-3901</td>
</tr>
<tr>
<td>(O) Revalor-H</td>
<td>Hoechst Roussel Vet</td>
<td>12799-810</td>
</tr>
<tr>
<td>(P) Revalor-S</td>
<td>Hoechst Roussel Vet</td>
<td>12799-809</td>
</tr>
<tr>
<td>(Q) Synovex H</td>
<td>Port Dodge Labs</td>
<td>0856-3904</td>
</tr>
<tr>
<td>(R) Synovex H</td>
<td>Port Dodge Labs</td>
<td>0856-3904</td>
</tr>
<tr>
<td>(S) Synovex Plus</td>
<td>Fort Dodge Laboratories</td>
<td></td>
</tr>
</tbody>
</table>

19 CSR 30-1.011 Definitions

PURPOSE: This rule contains definitions which establish the intended meaning of certain terms used throughout this chapter.

(1) As used in this chapter, the following terms shall have the meanings specified:

(A) Commercial container means any bottle, jar, tube, ampule or other receptacle in which a substance is held for distribution or dispensing to an ultimate user and, in addition, any box or package in which the receptacle is held for distribution or dispensing to an ultimate user. The term commercial container does not include any package liner, package insert of other material kept with or within a commercial container, nor any carton, crate, drug or other package in which commercial containers are stored or are used for shipment of controlled substances;

(B) Controlled substances administration record means the form used to record information when administering individual drug doses to patients;

(C) Dispenser means an individual practitioner, institutional practitioner, pharmacy or pharmacist who dispenses a controlled substance;

(D) Hospice means a public agency or private organization or subdivision of either of these that is primarily engaged in providing care to dying persons and their families and meets the standards specified in 19 CSR 30-35;

(E) Hospital employee means a nurse, physician, pharmacist or other responsible patient-care employee;

(F) Individual practitioner means a physician, dentist, veterinarian, optometrist or other individual licensed, registered or otherwise permitted by the United States or Missouri to dispense a controlled substance in the course of professional practice, but does not include a pharmacist, pharmacy or an institutional practitioner;

(G) Institutional practitioner means a hospital or other person (other than an individual) licensed, registered or otherwise permitted by the United States or Missouri to dispense a controlled substance in the course of professional practice, but does not include a pharmacy;

(H) Long-term care facility means a nursing home, retirement care facility, mental care facility or other facility or institution which provides extended health care to residents;

(I) Name means the official name, common or usual name, chemical name or brand name of a substance;

(J) Nurse means a registered or licensed practical nurse licensed under Chapter 335, RSMo;

(K) Patient care areas means any area of a hospital where medical attention is rendered to a patient;

(L) Pre-hospital emergency medical service means an emergency medical services system as defined in Chapter 190, RSMo providing services to persons prior to admission to a hospital;

(M) Prescription means an order for medication which is dispensed to or for an ultimate user but does not include an order for medication which is dispensed for immediate administration to the ultimate user. (For example, an order to dispense a drug to a bed patient for immediate administration in a hospital is not a prescription);

(N) Readily retrievable means that certain records are kept by automatic data processing systems or other electronic or mechanized record keeping systems in a manner that they can be separated out from all other records; and/or records are kept on which certain items are asterisked, redlined, highlighted or in some other manner visually identifiable apart from other items appearing on the records; and records are provided within three working days of a request;

(O) Registration means a Missouri controlled substances registration;

(P) Reregistration means a registration issued to a person who was previously registered and whose application for reregistration was received by the Department of Health prior to the expiration of the previous registration;

(Q) Temporary location registration means a registration issued to an individual practitioner who:

1. Has a current Missouri professional license to practice and is registered with the Department of Health at the address listed on his/her professional license;

2. Has a federal Drug Enforcement Administration registration that is valid in Missouri;

3. Anticipates practicing in Missouri within the next 12 months;

4. Does not practice for more than 90 consecutive calendar days at any location;

5. Maintains a record of the date(s) and location(s) of all practice activity in Missouri and makes the record available to the Bureau of Narcotics and Dangerous Drugs. This record shall be retained for two years;

6. Maintains all required controlled substance records at each location;

7. Does not receive or stock controlled substances at any location;

(R) Training program registration means a registration issued to an individual practitioner participating in a postgraduate medical education training program approved by a Missouri professional licensing board.

(2) Any term not defined in this rule shall have the definition set forth in Chapter 195, RSMo.


19 CSR 30-1.013 Miscellaneous Fees

PURPOSE: This rule establishes and fixes certain fees and charges statutorily authorized to be made by the Department of Health


State v. Miller, 588 SW2d 237 (Mo. App. 1979). Evidence of the presence of amphetamine is sufficient to support a controlled substances conviction; no quantitative analysis is necessary. Those rules refiled between January 1 and March 31, 1976 were not required to be published under section 536.021, RSMo. Also, courts must take judicial notice of the contents of the Code of State Regulations.

Selvey v. State, 578 SW2d 64 (Mo. App. 1979). Phenmetrazine, originally established statutorily as a Schedule III controlled substance, was rescheduled by the Division of Health to Schedule II. Such a rescheduling is within the statutory power granted the Division of Health and does not usurp the legislative power of the general assembly.

State v. Davis, 450 SW2d 168 (Mo. App. 1970). Statutes which direct the Division of Health to prepare a list of drugs classified as barbiturates and stimulants, the sale of which are made unlawful by statute, does not violate the Missouri Constitution prohibition in Article I, section 31 against delegation of authority to an agency to make a rule fixing a fine or imprisonment as punishment for its violation.
in provisions codified in Chapters 195 and 610, RSMo.

(1) Fees for copies of public records or other documents:
   (A) Copy, per page $0.25
   (B) Research fee, per hour $15.00

(2) Payment of fee may be required in advance.

(3) Fees are nonrefundable.


19 CSR 30-1.015 Registration Fees and Implementation of Three-Year Cycle

PURPOSE: This rule establishes fees for various types of registration, a late registration fee, manner of payment, and exemption from the registration fee, and implements a conversion for registrations to last 36 months.

(1) For each registration or re-registration to—
   (A) Manufacture controlled substances, the registrant shall pay a fee of $200;
   (B) Distribute controlled substances, the registrant shall pay a fee of $200;
   (C) Disperse controlled substances listed in Schedules II–V or to conduct research or instructional activities with those substances, the registrant shall pay a fee of $90;
   (D) Conduct research or instructional activities with a controlled substance listed in Schedule I, the registrant shall pay a fee of $90;
   (E) Conduct chemical analysis with controlled substances listed in any schedule, the registrant shall apply for exemption by completing appropriate sections of the application;
   (F) Import or export controlled substances, the registrant shall pay a fee of $200;
   (G) Dispense controlled substances listed in Schedules II–V by an individual practitioner who has a training program registration or a temporary location registration, the registrant shall pay an annual fee of $30.

(2) Not withstanding the provisions of (1)(A)–(G) of this rule, the following shall apply:
   (A) Each registrant shall pay a fee of $30 for a registration during the first year of implementation of this rule;
   (B) After the first year of implementation of this rule, the fees set forth in (1)(A)–(G) shall apply;
   (C) For the first year of implementation of this rule, each registration issued shall be current and effective for a period of not less than 12 months, but not more than 36 months;
   (D) Each registration received during the first year of implementation of this rule shall be randomly assigned an expiration date by a computer;
   (E) Temporary location registrations and training program registrations received during the first year of implementation of this rule may be assigned to a single group, and their expiration date may be less than 12 months;
   (F) Re-registrations issued during subsequent years shall be effective for 36 months.

(3) Lapsed Registration Fee. A late charge of $10 must be submitted with the original registration fee if an application is submitted more than 15 days after a previous registration has expired.

(4) Time and Method of Payment and Refunds. Registration and re-registration fees shall be paid at the time when the application for registration or re-registration is submitted for filing. Payment should be made in the form of a personal, certified or cashier’s check or money order payable to Department of Health. This is a nonrefundable processing fee. Payments made in the form of stamps, foreign currency or third-party endorsed checks will not be accepted.

(5) Persons Exempt From Fee. The Department of Health shall exempt the following persons from payment of a fee for registration or re-registration:
   (A) Any official or agency of the United States Army, Navy, Marine Corps, Air Force, Coast Guard, Veterans Administration or Public Health Service who is authorized to procure or purchase controlled substances for official use;
   (B) Any official, employee or other civil officer or agency of the United States or state or any political subdivision or agency who is authorized to purchase controlled substances, to obtain these substances from official stocks, to dispense or administer these substances, to conduct research, instructional activities or chemical analysis with these substances, or any combination of them, in the course of his/her official duties or employment;
   (C) In order to claim exemption from payment of a registration or re-registration fee, the registrant shall apply for exemption by completing appropriate sections of the application;
   (D) Exemption from payment of a registration or re-registration fee does not relieve the registrant of any other requirements or duties prescribed by law;
   (E) Any registration that is exempt from payment pursuant to this section shall be valid only when authorized persons are conducting activities in the course of their official duties or employment.


19 CSR 30-1.017 Registration Process

PURPOSE: This rule establishes the period and expiration of registration, the process of applying for registration, and information required to complete an application for registration.

(1) Period of Registration.
   (A) Any registration, except a re-registration, shall be current and effective for 36 months from the date issued or until the expiration date assigned at the time the registration is issued. A re-registration shall be current and effective for 36 months from the expiration date of the previous registration, provided that the application for re-registration was received prior to the expiration of the previous registration. No person who is required to be registered shall conduct any activity for which registration is required without a current registration.
   (B) At the time any registration is issued, the registration shall be assigned to one of 12 groups which shall correspond to the months of the year. The expiration date of all registrations within any group shall be the last day of the month designated for that group.
   (C) Registrations for manufacturers and distributors may be assigned to a single group, and the expiration date may be less than 36 months from the date the registration was issued.
   (D) Temporary location registrations and training program registrations may be
assigned to a single group, and the expiration date may be less than 12 months from the date the registration was issued.

(E) A certificate of registration shall be provided to the registrant which shall include the name and address of the registrant, the expiration date of the registration and a registration number for the convenience of identifying a registration or a registrant. The same registration number may be used for a new registration for the same person.

(2) Application for Registration.
   (A) Any person who is required to be registered and who is not so registered may apply for registration at any time. No person required to be registered shall engage in any activity for which registration is required until the application for registration is processed and the registration is issued.
   (B) Applications for registration shall be on forms designated by the Department of Health, and are incorporated into this rule by reference as follows: Form MO 580-2322. Application forms may be requested from the Missouri Department of Health, P.O. Box 570, Jefferson City, MO 65102-0570.
   (C) An application form containing the original signature of the applicant must be provided to the Department of Health with any required fee.
   (D) An application which does not contain or is not accompanied by the required information or fee may be denied 60 days after notifying the applicant of the deficiency.
   (E) An application may be withdrawn by making a written request to the Department of Health.

(3) Application Information. All applicants shall make full, true and complete answers on the application. The Department of Health may require an applicant to submit documents or written statements of fact relevant to the application as considered necessary to determine whether the application should be granted. The failure of the applicant to provide these documents or statements within 60 days after being requested to do so shall be considered to be a waiver by the applicant of an opportunity to present these documents or facts for consideration in granting or denying the application.

AUTHORITY: section 195.195, RSMo 1994.*

MISSOURI DEPARTMENT OF HEALTH
BUREAU OF NARCOTICS AND DANGEROUS DRUGS
APPLICATION FOR MISSOURI CONTROLLED SUBSTANCES REGISTRATION

Name & Address - Information must be TYPED or PRINTED. Only 5 lines are allowed. Name must appear on the first line. The manner in which this information is placed on the application is the way your certificate of registration will read. Please use the address of Missouri office or practice location. DO NOT USE a P.O. Box, unless in conjunction with a street address. The name and address must correspond with those provided on the federal DEA application.

REGISTRANT NAME AND ADDRESS OF MISSOURI PLACE OF BUSINESS (INCLUDE ZIP CODE)

[Field for registrant's name and address]

IF INFORMATION AT LEFT IS INCORRECT OR HAS CHANGED, PLEASE CORRECT BELOW:

1. 
2. 
3. 
4. 
5. 

CITY STATE ZIP CODE

WARNING: Section 195.040 RSMo, provides that the registration of any person who furnishes false or fraudulent material information in an application may be denied, revoked or suspended.

INSTRUCTIONS FOR COMPLETING APPLICATION

1. Please Print or Type all entries in black or blue ink.
2. No registration may be issued unless a completed application form has been received with fee ($30) as required.
   - Original signature is required.
   - Registration fee ($30) is a processing fee and is non-refundable.
   - An incomplete application will be returned for completion. This will delay processing.
3. Make check or money order payable to: Missouri Department of Health
4. Mail completed application and fee to: Missouri Department of Health
   Attn: Fee Receipt Unit
   P.O. Box 570
   Jefferson City, MO 65102-0570

1. REGISTRATION CLASSIFICATION

   • Check only one class of business activity. A separate application and fee ($30) must be submitted for each business activity at the same or different locations.
   • Practitioners - Practitioners with multiple office locations or practice sites need only be registered at one practice location unless controlled substances will be ordered, stocked or dispensed at each location; in which case, registrations are required at all locations.
   • Registered Professional Nurses - May administer or dispense controlled substances under a written collaborative practice arrangement or supervision agreement. The collaborating or supervising physician must also register separately at the practice site to order and stock controlled substances, including samples.

(CHECK ONE ☐ ONLY)

☐ MD ☐ DVM ☐ DPM ☐ OD (can only prescribe) ☐ Nursing Home Emergency Kit
☐ DO ☐ DDS ☐ DMD ☐ Retail Pharmacy ☐ Narcotic Treatment Program
☐ RN (may not prescribe controlled substances) ☐ Hospital ☐ Emergency Medical Service
☐ Researcher ☐ Analytical Lab ☐ Animal Shelter ☐ Teaching Institution (Instructional purposes only)
☐ Other __________________________

2. DRUG SCHEDULES: (Check all schedules in which you intend to prescribe or otherwise handle controlled substances.)

☐ Schedule 1 ☐ Schedule 2 ☐ Schedule 3 ☐ Schedule 4 ☐ Schedule 5

Rebecca McDowell Cook (10/31/00)  CODE OF STATE REGULATIONS 13
3. EXEMPT OFFICIAL

Check this box if applicant is a local, state or federal official or institution claiming exemption from fee. The address on the application must be that of the affiliated federal, state or local government entity. A registration fee is not required and Item 3 must be completed. NOTE: Registering under a governmental fee-exempt registration limits the registrant's controlled substance authority to the governmental practice only. If a practitioner wishes to have controlled substance authority outside of governmental practice or site, they must pay the appropriate fee.

☐ Check if exempt. Name of Governing unit. __________________________

4. LICENSURE STATUS AND HISTORY

APPLICANTS MUST ANSWER EACH OF THE FOLLOWING.

State license - A Missouri Controlled Substances Registration is based upon the applicant being in compliance with applicable federal, state and local law. Possession of a current Missouri license to practice your profession or conduct your business is required. If you have applied for state license or a federal DEA registration and it has not been issued, complete question 4A & 4D with "pending". If you are not required to have a federal DEA registration (nursing home emergency kit or non-prescribing veterinarian acting as an agent of another veterinarian) complete question 4D with "NA". Questions 4B and 4C must be answered. If either of the questions 4B or 4C are answered "YES," a letter of explanation and certified copies of court or appropriate documents must be attached to the application or be on file with the Bureau of Narcotics and Dangerous Drugs.

A. Are you currently licensed and registered by the state to practice your profession under laws of this state?  ☐ YES ☐ NO

Enter Missouri professional license number, pharmacy permit number, hospital license number, etc. # __________________

B. Has the individual applicant or any officer of the corporate applicant or any individual employed by the applicant having access to controlled substances pled guilty or nolo contendere, or been convicted of any violation of any state or federal law relating to the possession, manufacture, distribution, dispensing or prescribing of controlled substances?  ☐ YES ☐ NO

If yes, attach a letter of explanation with certified copies of court documents. If you have submitted these documents to the Bureau of Narcotics and Dangerous Drugs in the past, please check "On File."

C. Has any state or federal controlled substances registration or any state professional license or registration held by the applicant or any application therefor or renewal thereof ever been surrendered, revoked, suspended, denied, restricted or placed on probation or is such action pending?  ☐ YES ☐ NO

If yes, attach a letter of explanation with certified copies of administrative documents. If you have submitted these documents to the Bureau of Narcotics and Dangerous Drugs in the past, please check "On File."

D. Enter Federal number that has been issued to you by the Drug Enforcement Administration _______ _______ _______ _______ _______ _______

E. Enter Social Security number _______ _______ _______ _______ _______ _______ (See attached disclosure notice)

F. Date of Birth _______ _______ _______ _______ _______ _______

G. Enter business or office phone number _______ _______ _______ _______ _______

H. County of business __________________________

5. SIGNATURE

The application must be signed by the following: Practitioner: individual applicant; hospital, surgery center or nursing home: administrator or chief executive officer; emergency medical service: physician medical director; pharmacy or other entity: pharmacist, officer, administrator, manager, or other person authorized by entity.

PLEASE TYPE OR PRINT NAME OF INDIVIDUAL APPLICANT

TITLE OF APPLICANT

SIGNATURE OF APPLICANT

DATE APPLICATION IS SUBMITTED

Upon receipt of an approved application and fee, a registration certificate will be prepared and issued within 15 business days. If you wish to retain a copy of this application for your records, you may make a photocopy. Your cancelled check is your receipt.
NOTE: Once your Missouri Controlled Substances Registration is issued, an application is automatically sent to you at your previously registered address 60 days prior to your expiration date. In order to receive an application, you must keep your address current by notifying:

Missouri Bureau of Narcotics and Dangerous Drugs
P.O. Box 570
Jefferson City, MO 65102-0570
(573) 751-6333 or FAX (573) 526-2560

Change of address must be submitted to Bureau of Narcotics and Dangerous Drugs in writing, allowing 15 business days to process.

NOTE: If an application to renew is not received by the registrant 50 days prior to the registration’s expiration date, it is ultimately the responsibility of the registrant to contact the Missouri Bureau of Narcotics and Dangerous Drugs for an application for a Missouri Controlled Substances Registration.

Social Security Number Disclosure Notice

The individual signing the application must provide their social security number pursuant to state and federal law. Corporations are not required to submit a social security number. Practitioners such as physicians, dentists, veterinarians, etc., are registered individually and must provide their social security number even though their practice may be incorporated.

Failure to provide your social security number will require the return of your application to you for completion. Continued failure or refusal to provide your social security number is grounds for denial of your application.

Pursuant to state and federal law, licensing authorities must assemble your social security number with other relevant information (name, address, etc.) and supply the data to the Division of Child Support Enforcement of the Missouri Department of Social Services to be used in a database for the following purposes:

1. locating individuals who are under obligation to pay child support or provide child custody or visitation rights, against whom such an obligation is sought or to whom such an obligation is owed;
2. identifying whether an individual who owes overdue child support or who had failed to comply with a subpoena relating to paternity or child support proceedings holds or has applied for a professional or occupational license (under certain circumstances, a person who owes overdue support or fails to comply with a subpoena relating to the above-stated proceedings may be subject to an order of a court, after notice and opportunity for hearing in that court, suspending, withholding or restricting the person’s license).

¹Senate Bill 361, 89th General Assembly, First General Session (1997); Personal Responsibility and Work opportunity
19 CSR 30-1.019 Registration Location

PURPOSE: This rule establishes requirements for the physical location of a registration.

(1) A controlled substance registration shall be issued at a U.S. Postal Service street address.

(2) A controlled substance registration shall be issued to an individual practitioner at a Missouri practice location where controlled substance and other patient care activities occur, except:

(A) When an individual practitioner applies for a registration and no practice location is known, the registration shall be issued to the address where the practitioner’s professional license to practice in Missouri is issued. No controlled substances shall be stocked, administered or dispensed at this location. When a practice location is determined the practitioner shall notify the Department of Health in writing, including the registrant’s signature, of the address and effective date prior to conducting controlled substance activities at the practice location. No fee shall be required for this change. When the Department of Health has been notified and the change is completed, the practitioner shall have authority to stock, administer or dispense controlled substances at this location;

(B) When an individual practitioner has a temporary location registration, the registration shall be issued to the address where the practitioner’s professional license to practice in Missouri is issued. A practitioner with a temporary location registration shall:

1. Have a current Missouri professional license to practice and be registered with the Department of Health at the address listed on his/her professional license;
2. Have a federal Drug Enforcement Administration registration that is valid in Missouri;
3. Anticipate practicing in Missouri within the next 12 months;
4. Not practice for more than 90 consecutive calendar days at any location;
5. Maintain a record of the date(s) and location(s) of all practice activity in Missouri and make the record available to the Bureau of Narcotics and Dangerous Drugs. This record shall be retained for two years;
6. Maintain all required controlled substance records at each location;
7. Not receive or stock controlled substances at any location.

AUTHORITY: section 195.195, RSMo 1994.*

19 CSR 30-1.020 List of Exempted Substances
(Rescinded November 30, 2000)


PURPOSE: This rule defines the requirements for controlled substance registrations for separate activities and for separate sites, and defines when a separate registration is not required.

(1) Independent Activities. The following eight groups of activities are deemed to be independent of each other and require separate registration:

(A) Manufacturing controlled substances;
(B) Distributing controlled substances, except:
   1. A dispenser distributing less than 5% of the total combined dosage units of controlled substances distributed and dispensed in a calendar year shall be exempt from obtaining a separate registration for distributing;
   2. A dispenser distributing more than 5% of the total combined dosage units of controlled substances distributed and dispensed in a calendar year must obtain a separate registration as a distributor but shall be exempt from maintaining separate inventories under 19 CSR 30-1.042;
   (C) Dispensing controlled substances listed in Schedules II–V;
   (D) Conducting research and instructional activities with controlled substances listed in Schedule I;
   (E) Conducting research with controlled substances listed in Schedules II–V;
   (F) Conducting a narcotic treatment program with narcotic controlled substances listed in Schedules II–V;
   (G) Conducting instructional activities with controlled substances listed in Schedules II–V;
   (H) Importing controlled substances;
   (I) Exporting controlled substances;
   (J) Conducting chemical analysis with controlled substances.

3. An office used by a practitioner (who is registered at another location) where controlled substances are prescribed but neither administered nor otherwise dispensed as a regular part of the professional practice of the practitioner at the office and where no supplies of controlled substances are maintained;

4. A location on the immediate or contiguous property of a hospital, provided that the location is owned and operated by the hospital and controlled substances are not dispensed for use away from the location;

5. A separate location from a registered pre-hospital emergency medical service location where an emergency vehicle is housed that does not have a permanent location of operation and which rotates between locations at least every 30 days for operational reasons other than controlled substance registration;

6. A pre-hospital emergency medical service located outside the state of Missouri that renders assistance to a pre-hospital emergency medical service located in the state of Missouri under a mutual aid contract in the case of an emergency, major catastrophe or other unforeseen event that jeopardizes the ability of the local Missouri pre-hospital emergency medical service to promptly respond.

(B) A separate registration is not required for each separate practice location for an individual practitioner who has a temporary location registration.


19 CSR 30-1.030 Requirements for Controlled Substances Registration

(Rescinded November 30, 2000)


19 CSR 30-1.031 Physical Security Requirements

PURPOSE: This rule requires applicants and registrants to maintain security controls and procedures to prevent theft and diversion of controlled substances.

1. All applicants and registrants shall provide effective controls and procedures to guard against theft and diversion of controlled substances. In order to determine whether a registrant has provided effective controls against diversion, the Department of Health shall use the security requirement set forth in 19 CSR 30-1.032–19 CSR 30-1.034 as standards for the physical security controls and operating procedures necessary to prevent diversion. Substantial compliance with these standards may be deemed sufficient by the Department of Health after evaluation of the overall security system and needs of the applicant or registrant.

2. Physical security controls shall be commensurate with the schedules and quantity of controlled substances in the possession of the registrant in normal business operations. If a controlled substance is transferred to a different schedule, or a noncontrolled substance is listed on any schedule, or the quantity of controlled substances in the possession of the registrant in normal business operations significantly increases, physical security controls shall be expanded and extended accordingly.

3. All registrants who receive or transfer substantial quantities of controlled substances in normal business operations shall employ security procedures to guard against in-transit losses.
19 CSR 30-1.032 Security for Nonpractitioners

PURPOSE: This rule describes specific actions required of nonpractitioner registrants to maintain effective security.

(1) Before distributing a controlled substance to any person who the registrant does not know to be registered to possess the controlled substance, the registrant shall make a good faith inquiry either with the federal Drug Enforcement Administration (DEA) or with the Department of Health to determine that the person is registered to possess the controlled substance.

(2) The registrant shall design and operate a system to disclose to the registrant suspicious orders of controlled substances. The registrant shall inform the Department of Health of suspicious orders when discovered by the registrant. Suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern and orders of unusual frequency.

(3) The registrant shall notify the Department of Health of any theft or significant loss of any controlled substances upon discovery of this theft or loss.

(A) The registrant shall complete and submit a Report of Loss, Theft or Diversion of Controlled Substances or Regulated Chemicals to the Department of Health no later than seven business days after the discovery of such a loss. If the extent of the loss cannot be fully determined in that time frame, the registrant shall contact the Department of Health to request permission to submit an interim report and arrange for a complete report to be completed and submitted. The registrant may attach a copy of a completed Drug Enforcement Administration Loss Form in lieu of completing the back or second page of a Report of Loss, Theft or Diversion of Controlled Substances or Regulated Chemicals form. In the event of theft, diversion or suspected theft or diversion, the report submitted to the Department of Health shall be accompanied by or followed by a summary of the internal investigation performed, the outcome of the investigation, and a copy of any law enforcement agency report completed if applicable.

(B) If an insignificant amount of a controlled substance is lost during lawful activities authorized under Chapter 195, RSMo, the reason for the loss or a description of what occurred, the name of the drug and the amount lost shall be documented in writing, signed by the registrant and attached or filed with the last completed annual inventory.

(4) The registrant shall not distribute any controlled substance as a complimentary sample to any potential or current customer without the prior written request of the customer, to be used only for satisfying the legitimate medical needs of patients of the customer and only in reasonable quantities. The request must contain the name, address and registration number of the customer and the name of the specific controlled substance desired. The request shall be preserved by the registrant with other records of distribution of controlled substances. In addition, the requirements for order forms shall be complied with for any distribution of a controlled substance listed in Schedule I or II.

AUTHORITY: section 195.195, RSMo 1994.*


19 CSR 30-1.033 Hearing Procedures on Controlled Substances Registration

(Rescinded November 30, 2000)


19 CSR 30-1.034 Security for Practitioners

PURPOSE: This rule describes specific actions required of practitioner registrants to maintain effective security. This rule also creates and defines the form which must be used by a registrant to report any theft or loss of controlled substances to the Department of Health.

(1) Physical Security.

(A) Controlled substances listed in Schedules I and II shall be stored in a securely locked, substantially constructed cabinet. (B) Controlled substances listed in Schedules III, IV and V shall be stored in a securely locked, substantially constructed cabinet. However, pharmacies may disperse these substances throughout the stock of non-controlled substances in such a manner as to obstruct the theft or diversion of the controlled substances.

(C) This rule also shall apply to nonpractitioners authorized to conduct research or chemical analysis under another registration.

(2) Other Security.

(A) The registrant shall not employ as an agent or employee who has access to controlled substances any person who has been found guilty or entered a plea of guilty or nolo contendere in a criminal prosecution under the laws of any state or of the United States for any offense related to controlled substances or who has had an application for a state or federal controlled substance registration denied or has had his/her registration revoked or surrendered for cause at any time. For purposes of this subsection, the term for cause means a surrender in place of or as a consequence of any federal or state administrative, civil or criminal action resulting from an investigation of the individual’s handling of controlled substances.

1. A registrant may apply in writing to the Department of Health for a waiver of subsection (2)(A) of this rule for a specific employee.

2. The Department of Health may issue a written waiver to any registrant upon determination that a waiver would be consistent with the public health and safety. In making this determination, the Department of Health shall consider—the duties of the employee, the circumstances surrounding the conviction, the length of time since the conviction was entered, whether a waiver has been granted by the federal Drug Enforcement Administration (DEA) pursuant to 21 CFR 1301.76, the security measures taken by the employer to prevent the theft and diversion of controlled substances, and any other factors consistent with public health and safety.

(B) A registrant shall notify the Department of Health of the theft, diversion or significant loss of any controlled substances or regulated chemicals upon discovery.

1. The registrant shall complete and submit a Report of Loss, Theft or Diversion of Controlled Substances or Regulated Chemicals to the Department of Health no later than seven business days after the discovery of such a loss. The loss report form shall be incorporated into this rule by reference. If the extent of the loss cannot be fully

19 CSR 30-1.035...
determined in that time frame, the registrant shall contact the Department of Health to request permission to submit an interim report and arrange for a complete report to be completed and submitted. The registrant may attach a copy of a completed Drug Enforcement Administration Loss Form in lieu of completing the back or second page of a Report of Loss, Theft or Diversion of Controlled Substances or Regulated Chemicals form. In the event of theft, diversion or suspected theft or diversion, the report submitted to the Department of Health shall be accompanied by or followed by a summary of the internal investigation performed, the outcome of the investigation, and a copy of any law enforcement agency report completed if applicable.

2. If an insignificant amount of a controlled substance is lost during lawful activities authorized under Chapter 195, RSMo, the reason for the loss or a description of what occurred, the name of the drug and the amount lost shall be documented in writing, signed by the registrant and attached or filed with the last completed annual inventory.

**AUTHORITY:** section 195.195, RSMo 1994.*

**MISSOURI DEPARTMENT OF HEALTH**  
**BUREAU OF NARCOTICS AND DANGEROUS DRUGS**  
**REPORT OF LOSS OR THEFT OF CONTROLLED SUBSTANCES OR CHEMICALS**

Missouri regulations require registrants to submit a report of any loss or theft of controlled substances or chemicals to the Missouri Bureau of Narcotics and Dangerous Drugs. Please print or type all information in blue or black ink.

<table>
<thead>
<tr>
<th>NAME AND ADDRESS OF REGISTRANT (AS PRINTED ON REGISTRATION)</th>
<th>2. PHONE NUMBER (INCLUDE AREA CODE)</th>
<th>3. DATE OF THEFT, LOSS OR DIVERSION (IF UNKNOWN, DATE DISCOVERED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITY</td>
<td>4. MISSOURI CONTROLLED SUBSTANCES REGISTRATION NUMBER (BNDD)</td>
<td>5. FEDERAL DEA REGISTRATION NUMBER</td>
</tr>
<tr>
<td>STATE ZIP CODE</td>
<td></td>
<td>6. COUNTY IN WHICH LOCATED</td>
</tr>
</tbody>
</table>

7. **PRINCIPAL BUSINESS OF REGISTRANT (CHECK ONE BOX ONLY)**

- [ ] MD  
- [ ] DO  
- [ ] DPM  
- [ ] NURSING HOME KIT  
- [ ] DISTRIBUTOR  
- [ ] OD  
- [ ] DVM  
- [ ] PHARMACY  
- [ ] NARCOTIC TREATMENT PROGRAM  
- [ ] IMPORTER/EXPORTER  
- [ ] DDS  
- [ ] DMD  
- [ ] HOSPITAL  
- [ ] TEACHING INSTITUTION  
- [ ] OTHER (SPECIFY)  
- [ ] ANP  
- [ ] AMBULANCE  
- [ ] MANUFACTURER

8. **WAS THEFT REPORTED TO POLICE?**  
- [ ] YES  
- [ ] NO

9. **NAME AND TELEPHONE NUMBER OF POLICE DEPARTMENT (INCLUDE AREA CODE)**

10. **NO. OF THEFTS OR LOSSES REGISTRANT HAS EXPERIENCED IN THE PAST 24 MONTHS**

11. **TYPE OF LOSS OR DIVERSION**

- [ ] BREAK-IN/BURGLARY  
- [ ] EMPLOYEE THEFT  
- [ ] LOST IN TRANSIT  
- [ ] ROBBERY  
- [ ] FORGED OR FALSIFIED RECORDS  
- [ ] OTHER (EXPLAIN)

12. **NAME(S) OF INDIVIDUALS RESPONSIBLE FOR THEFT OR DIVERSION.**

SPECIAL SOCIAL SECURITY NUMBER AND DATE OF BIRTH OF INDIVIDUAL(S) RESPONSIBLE FOR THEFT OR DIVERSION, IF KNOWN.

13. **SUMMARY OF INVESTIGATION (INCLUDING COPIES OF LAW ENFORCEMENT AGENCY REPORTS WHEN APPLICABLE).**

- [ ] ATTACHED  
- [ ] WILL FOLLOW BY _____________.  

(DATE)

---

MO 590-2283 (5-98)  
CONTINUE ON REVERSE  
NDD-15
# LIST OF CONTROLLED SUBSTANCES LOST

<table>
<thead>
<tr>
<th>TRADE NAME OF SUBSTANCE OR PREPARATION</th>
<th>NAME OF CONTROLLED SUBSTANCE IN PREPARATION</th>
<th>DOSAGE STRENGTH AND FORM</th>
<th>QUANTITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desoxyn</td>
<td>Methamphetamine Hydrochloride</td>
<td>5 Mg Tablets</td>
<td>3 x 100</td>
</tr>
<tr>
<td>Demerol</td>
<td>Meperidine Hydrochloride</td>
<td>50 Mg/ml Vial</td>
<td>5 x 30 ml</td>
</tr>
<tr>
<td>Robitussin A-C</td>
<td>Codeine Phosphate</td>
<td>2 Mg/cc Liquid</td>
<td>12 pints</td>
</tr>
</tbody>
</table>

1.  
2.  
3.  
4.  
5.  
6.  
7.  
8.  
9.  
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 

I certify that the foregoing information is correct to the best of my knowledge and belief.

<table>
<thead>
<tr>
<th>PRINT NAME</th>
<th>SIGNATURE</th>
<th>TITLE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MO 580-0285 (5-96)
19 CSR 30-1.035 Requirements for Prescribing, Dispensing and Administering Controlled Substances
(Rescinded November 30, 2000)


19 CSR 30-1.036 Disposing of Unwanted Controlled Substances
(Rescinded November 30, 2000)


19 CSR 30-1.040 Dispensing and Distribution of Controlled Substances in Certain Situations

PURPOSE: These rules provide for the dispensing of Schedule II controlled substances, for the dispensing of Schedule II controlled substances in emergency situations and for the emergency distribution of a controlled substance.

(1) Emergency Dispensing of Schedule II Controlled Substances. In the case of a bona fide emergency situation, as defined by the Department of Health, a pharmacist may dispense a Schedule II controlled substance upon receiving oral authorization of a prescribing practitioner; provided, that—

(A) The quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. Prescribing or dispensing beyond the emergency period must be pursuant to a written prescription;

(B) The prescription immediately shall be reduced to writing by the pharmacist and shall contain all information, except for the prescribing practitioner’s signature;

(C) If the prescribing practitioner is not known to the pharmacist, she/he must make reasonable effort to determine that the oral authorization came from a practitioner, by verifying his/her phone number against that listed in the directory and other good faith efforts to insure his/her identity; and

(D) Within seventy-two (72) hours after authorizing an emergency oral prescription, the prescribing practitioner must cause a written prescription for the emergency quantity prescribed to be delivered to the dispensing pharmacist. The prescription shall have written on its face authorization for emergency dispensing. The written prescription may be delivered to the pharmacist in person or by mail, but if delivered by mail it must be postmarked within the seventy-two (72)-hour period. Upon receipt, the dispensing pharmacist shall attach this prescription to the oral emergency prescription which had earlier been reduced to writing. The pharmacist shall notify the Department of Health if the prescribing practitioner fails to deliver a written prescription to him/her; failure of the pharmacist to do so shall void the authority conferred by this section to dispense without a written prescription of a prescribing practitioner.

(2) Definition of Emergency Situation. For the purpose of authorizing an oral prescription of a controlled substance listed in Schedule II of the controlled substances law (sections 195.010–195.320, RSMo), the term emergency situation means those situations in which the prescribing practitioner determines that—

(A) Immediate administration of a controlled substance is necessary for proper treatment of the intended ultimate user;

(B) No appropriate alternative treatment is available, including administration of a drug which is not a controlled substance under Schedule II; and

(C) It is not reasonably possible for the prescribing practitioner to provide a written prescription to be presented to the person dispensing the substance prior to the dispensing.

(3) Emergency Controlled Substance Distribution by a Pharmacy. An emergency means a situation where a quantity of a controlled substance must be dispensed by a pharmacy to a patient who does not have an alternative source for that substance reasonably available to him/her and the pharmacy cannot obtain that substance through its normal distribution channels within the time required to meet the immediate needs of the patient for that substance. In the event of an emergency, a pharmacy may distribute (without being registered as a distributor) a controlled substance in Schedule III, IV or V to a second pharmacy in order for that pharmacy to dispense the substance; provided, that—

(A) The amount distributed does not exceed the amount required by the second pharmacy for his/her immediate dispensing;

(B) The distribution is recorded as being dispensed by the first pharmacy and the second pharmacy records the substance as being received. Each pharmacy will retain a signed receipt of the distribution;

(C) The second pharmacy is registered to dispense the controlled substance to be distributed to him/her; and

(D) If the substance is a Schedule II controlled substance, an order form is required.

(4) Dispensing of Schedule V Substances, Requirement of Prescription.

(A) A pharmacist directly may dispense a controlled substance listed in Schedule V pursuant to a prescription. A prescription for a controlled substance listed in Schedule V may be refilled only as expressly authorized by the prescribing individual practitioner on the prescription. If this authorization is given, the prescription may not be refilled. A pharmacist dispensing those substances pursuant to a prescription shall label the substance and file the prescription.

(B) An individual practitioner may administer or dispense directly a controlled substance listed in Schedule V in the course of his/her professional practice without a prescription.

(C) An institutional practitioner may administer or dispense directly (but not prescribe) a controlled substance listed in Schedule V only pursuant to a written prescription signed by the prescribing individual practitioner or pursuant to an oral prescription made by a prescribing individual practitioner and promptly reduced to writing by the pharmacist (containing all information required except for the signature of the prescribing individual practitioner) or pursuant to an order for medication made by an individual practitioner which is dispensed for immediate administration to the ultimate user.

(5) Dispensing Without Prescription. A controlled substance listed in Schedule V which is not a prescription drug and determined under the federal Food, Drug and Cosmetic Act may be dispensed by a pharmacist without a prescription to a purchaser at retail; provided, that—

(A) Dispensing is made only by a pharmacist and not by a nonpharmacist employee even if under the supervision of a pharmacist (although after the pharmacist has fulfilled his/her professional and legal responsibilities, the actual cash transaction, credit transaction or delivery may be completed by a nonpharmacist);

(B) Not more than two hundred forty cubic centimeters (240 cc) eight ounces (8 oz.) of
any controlled substance containing opium, nor more than one hundred twenty cubic centimeters (120 cc) four ounces (4 oz.) of any other controlled substance nor more than forty-eight (48) dosage units of any controlled substance containing opium, nor more than twenty-four (24) dosage units of any other controlled substance may be dispensed at retail to the same purchaser in any given forty-eight (48)-hour period; 

(C) The purchaser is at least eighteen (18) years of age; 

(D) The pharmacist requires every pur-
chaser of a Schedule V controlled substance not known to him/her to furnish suitable identification (including proof of age where appropriate); 

(E) A bound record book for dispensing of Schedule V controlled substances is main-
tained by the pharmacist. The book shall con-
tain the name and address of the purchaser, the name and quantity of controlled substance purchased, the date of each purchase and the name or initials of the pharmacist who dis-
pensed the substance to the purchaser (the book shall be maintained in accordance with recordkeeping requirements); and 

(F) A prescription is not required for dis-
tribution or dispensing of the substance pur-
suant to any other federal, state or local law.

AUTHORITY: section 195.195, RSMo 1986. * 
This rule was previously filed as 13 CSR 50-


19 CSR 30-1.041 Records Requirements

PURPOSE: This rule defines the record keep-
ing and inventory requirements for various classes of registrants.

(1) Persons Required to Keep Records.

(A) Each registrant shall maintain the records and inventory required by 19 CSR 30-1.041–19 CSR 30-1.052, except as exempted by 19 CSR 30-1.041–19 CSR 30-
1.052.

(B) Registered individual practitioners and institutional practitioners are required to keep records with respect to controlled substances which are prescribed, administered or dis-
pensed.

(C) A registered person using any con-
trolled substance in research conducted in conformity with an exemption granted under section 505(i) or 512(j) of the federal Food, Drug and Cosmetic Act (21 U.S.C. 355(i) or 360(j)) at a registered establishment which maintains records in accordance with either of those sections is not required to keep records if s/he notifies the Department of Health of the name, address and registration number of the establishment maintaining these records.

(D) A registered person using any con-
trolled substance in preclinical research or in teaching at a registered establishment which maintains records with respect to these sub-
stances is not required to keep records if s/he notifies the Department of Health of the name, address and registration number of the establishment maintaining the records.

(E) Notice required by subsection (1)(D) of this rule shall be given at the time the person applies for registration or re-registration and shall be made in the form of an attachment to the application, which shall be filed with the application.

(2) Maintenance of Records and Inventories. 
Every inventory and other record required to be kept under 19 CSR 30-1.041–19 CSR 30-
1.052, shall be kept by the registrant and be available, for at least two years from the date of the inventory or record, for inspecting and copying by authorized employees of the Department of Health, except that financial and shipping records (such as invoices and packing slips, but not executed order forms) may be kept at a central location rather than at the registered location if the registrant obtains from the Department of Health approval of his/her central record keeping system and a permit to keep central records. The permit to keep central records shall be subject to the following conditions:

(A) The permit shall specify the nature of the records to be kept centrally and the exact location where the records will be kept;

(B) The registrant agrees to deliver all or any part of these records to the registered location within three working days of receipt of a written request from the Department of Health for these records and if the Department of Health chooses to do so in lieu of requiring delivery of records to the regis-
tered location, to allow authorized employees of the Department of Health to inspect the records at the central location upon request by the employees without a warrant of any kind;

(C) The failure of the registrant to perform his/her agreements under the permit shall revoke, without further action, the permit and all other such permits held by the registrant under other registrations. In the event of a revocation of other permits under subsection (2)(C) of this rule, the registrant, within 30 days after the revocation, shall comply with the requirement that all records be kept at the registered location.

(3) Each registered individual practitioner, institutional practitioner, manufacturer, dis-
tributor, importer and exporter shall maintain inventories and records of controlled sub-
stances as follows:

(A) Inventories and records of controlled substances listed in Schedules I and II shall be maintained separately from all of the records of the registrant;

(B) Inventories and records of controlled substances listed in Schedules III, IV and V shall be maintained either separately from all other records of the registrant or in a form that the information required is readily retrievable from the ordinary business records of the registrant.

(4) Each registered pharmacy shall maintain the inventories and records of controlled sub-
stances as follows:

(A) Inventories and records of all con-
trolled substances listed in Schedules I and II shall be maintained separately from all other records of the pharmacy and prescriptions for these substances shall be maintained in a separate prescription file;

(B) Inventories and records of controlled substances listed in Schedules III, IV and V shall be maintained either separately from all other records of the pharmacy or in a form that the information required is readily retrievable from ordinary business records of the pharmacy and prescriptions for those substances shall be maintained in a separate pre-
scription file.

AUTHORITY: sections 195.050 and 195.195, 


19 CSR 30-1.042 Inventory Requirements

PURPOSE: This rule defines requirements for the form and maintenance of controlled substance inventories.

(1) General Requirements.

(A) Each inventory shall contain a com-
plete and accurate record of all controlled substances on hand on the date the inventory was taken. Controlled substances shall be deemed to be on hand if they are in the pos-
session of or under the control of the regis-
tant, including substances returned by a cus-
tomer, substances ordered by a customer but
not yet invoiced, substances stored in a warehouse on behalf of the registrant and substances in the possession of employees of the registrant intended for distribution as complimentary samples.

(5) Inventories of Manufacturers. Each registered manufacturer shall include the following information in his/her inventory:

(A) For each controlled substance in bulk form to be used in (or capable of use in) the manufacture of the same or other controlled or noncontrolled substances in finished form, the name of the substance and the total quantity of the substance to the nearest metric unit weight consistent with unit size (except that for inventories made in 1971, avoirdupois weights may be utilized where metric weights are not readily available);

(B) For each controlled substance in the process of manufacture on the inventory date the name of the substance, the quantity of the substance in each batch, stage of manufacture, or both, identified by the batch number or other appropriate identifying number and the physical form which the substance is to take upon completion of the manufacturing process (for example, granulations, tablets, capsules or solutions), identified by the batch number or other appropriate identifying number and if possible the finished form of the substance (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter) and the number or volume;

(C) For each controlled substance in finished form, the name of the substance; each finished form of the substance (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter); the number of units or volume of each finished form in each commercial container (for example, four 100 tablet bottles or three milliliter (3 ml) vials); the number of commercial containers of each finished form (for example, four 100 tablet bottles or six three milliliter (3 ml) vials);

(D) For each controlled substance not included in subsections (5)(A)–(C) of this rule (for example, damaged, defective or impure substances awaiting disposal, substances held for quality control purposes or substances maintained for extemporaneous compoundings), the name of the substance; the total quantity of the substance to the nearest metric unit weight or the total number of units of finished form; the reason for the substance being maintained by the registrant and whether the substance is capable of use in the manufacture of any controlled substance in finished form.

(6) Inventories of Distributors. Each registered distributor shall include in his/her inventory the same information required of manufacturers in subsections (5)(C) and (D) of this rule.

(7) Inventories of Dispensers and Researchers. Each person registered to dispense or conduct research with controlled substances and required to keep records shall include in his/her inventory the same information required of manufacturers in subsections (5)(C) and (D) of this rule. In determining the number of units of each finished form of a controlled substance in a commercial container which has been opened, the dispenser shall do as follows:

(A) If the substance is listed in Schedule I or II, s/he shall make an exact count or measure of the contents;

(B) If the substance is listed in Schedule III, IV or V, s/he shall make an estimated count or measure of the contents, unless the container holds more than 1,000 tablets or capsules in which case s/he must make an exact count of the contents.

(8) Inventories of Importers and Exporters. Each registered importer or exporter shall include in his/her inventory the same information required of manufacturers in subsections (5)(A), (C) and (D) of this rule. Each registered importer and exporter who also is registered as a manufacturer or as a distributor shall include in his/her inventory as an importer or exporter only those stocks of controlled substances that actually are separated from his/her stocks as a manufacturer or as a distributor (for example, in-transit or in storage for shipment).

(9) Inventories for Chemical Analysts. Each analytical laboratory registered to conduct chemical analysis with controlled substances shall include in its inventory the same information required of manufacturers in subsections (5)(A), (C) and (D) of this rule as to substances which have been manufactured, imported or received by the laboratory conducting the inventory. If less than one kilogram (1 kg) of any controlled substance (other than a hallucinogenic controlled substance listed in Schedule I) or less than twenty grams (20 g) of a hallucinogenic substance listed in Schedule I (other than lysergic acid diethylamide) or less than point five gram (0.5 g) of lysergic acid diethylamide, is on hand at the time of inventory, those substances need not be included in the inventory. Laboratories of the division may process up to one hundred fifty grams (150 g) of any hallucinogenic substance in Schedule I without regard to a need for an inventory of those substances.
19 CSR 30-1.044 Continuing Records General Requirements

PURPOSE: This rule sets requirements for the maintenance of ongoing controlled substance records.

(1) Every registrant required to keep records shall maintain on a current basis a complete and accurate record of each such substance manufactured, imported, received, sold, delivered, exported or otherwise disposed of by him/her.

(2) Separate records shall be maintained by a registrant for each registered location except as provided in 19 CSR 30-1.041(2). In the event controlled substances are in the possession or under the control of a registrant at a location for which s/he is not registered, the substance shall be included in the records of the registered location to which they are subject to control or to which the person possessing the substance is responsible.

(3) Separate records shall be maintained by a registrant for each independent activity for which s/he is registered.

(4) In recording dates of receipt, importation, distribution, exportation or other transfers, the date on which the controlled substances are actually received, imported, distributed, exported or otherwise transferred shall be used as the date of receipt or distribution of any documents of transfer (for example, invoices or packing slips).

(5) Records must be provided to the Department of Health within three working days upon request.


19 CSR 30-1.046 Records for Manufacturers, Distributors, Importers and Exporters

PURPOSE: This rule sets requirements for record keeping by manufacturers, distributors, importers and exporters of controlled substances.

(1) Records for Manufacturers. Each registered manufacturer shall maintain records with the following information:

(A) For each controlled substance in bulk form to be used in or capable of use in or being used in the manufacture of the same or other controlled or noncontrolled substances in finished form—

1. The name of the substance;
2. The quantity manufactured in bulk form by the registrant, including the date, quantity and batch or other identifying number of each batch manufactured;
3. The quantity received from other persons including the date and quantity of each receipt and the name, address and registration number of the other person from whom the substance was received;
4. The quantity used to manufacture the same substance in finished form including the date and batch or other identifying number of each manufacture; the quantity used in manufacture; the finished form (for example, ten milligram (10 mg) tablets or ten milligram (10 mg) concentration per fluid ounce or milliliter); the number of units of finished form manufactured; the quantity used in quality control; the quantity lost during manufacturing and the causes for the loss, if known; the total quantity of the substance contained in the finished form; the theoretical and actual yields and other information as is necessary to account for all controlled substances used in the manufacturing process;
5. The quantity used to manufacture other controlled and noncontrolled substances, including the name of each substance manufactured and the information required in paragraph (1)(A)5. of this rule;
6. The quantity distributed or disposed of in any other manner by the registrant (for example, distribution of complimentary samples or by destruction) including the date and manner of distribution or disposal, the name, address and registration number of the person to whom distributed and the quantity distributed or disposed;

(B) For each controlled substance in finished form—

1. The name of the substance;
2. Each finished form (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter) and the number of units or volume of finished form in each commercial container (for example, 100 tablet bottle or three milliliter (3 ml) vial);
3. The number of containers of each such commercial finished form manufactured from bulk form by the registrant, including the information required in paragraph (1)(A)5. of this rule;
4. The number of units of finished forms, commercial containers, or both, received from other persons, including the date and number of units, commercial containers, or both, in each receipt and the name, address and registration number of the person from whom the units were received;
5. The number of units of finished form, commercial containers, or both, imported directly by the registrant, including the date and the number of units, commercial containers, or both, in each importation;
6. The number of units, commercial containers, or both, manufactured by the registrant from units in finished form received from others or imported including: the date and batch or other identifying number of each manufacture; the operation performed (for example, repackaging or relabeling); the number of units of finished form used in the manufacture, the number manufactured and the number lost during the manufacture, with the causes for these losses, if known, and other information as is necessary to account for all controlled substances used in the manufacturing process;
7. The number of commercial containers distributed to other persons including the date of and number of containers in each distribution and the name, address and registration number of the person to whom the containers were distributed;
8. The number of commercial containers exported directly by the registrant, including the date, number of containers and export permit or declaration number for each exportation;
9. The number of units of finished forms, commercial containers, or both, distributed or disposed of in any other manner by the registrant (for example, by distribution of complimentary samples or by destruction), including the date and manner of distribution.

Rebecca McDowell Cook  (10/31/00)  CODE OF STATE REGULATIONS  25
or disposal, the name, address and registration number of the person to whom distributed and the quantity in finished form distributed or disposed.

(2) Records for Distributors. Each registered distributor shall maintain records with the following information for each controlled substance:

(A) The name of the substance;
(B) Each finished form (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter) and the number of units or volume of finished form in each commercial container (for example, 100 tablet bottle or three milliliter (3 ml) vial);
(C) The number of commercial containers of each such finished form received from other persons, including the date of and number of containers in each receipt and the name, address and registration number of the person from whom the containers were received;
(D) The number of commercial containers of each finished form imported directly by the registrant including the date of and the number of containers in each importation;
(E) The number of commercial containers of each finished form distributed to other persons, including the date of and number of containers in each distribution and the name, address and registration number of the person to whom the containers were distributed;
(F) The number of commercial containers of the finished form exported directly by the registrant, including the date of and the number of containers in each exportation;
(G) The number of units or volume of finished forms, commercial containers, or both, distributed or disposed of in any other manner by the registrant (for example, by distribution as complimentary samples) including the date and manner of distribution or disposal, the name, address and registration number of the person to whom distributed and the quantity of the substance in finished form distributed or disposed.

(3) Records for Importers. Each registered importer shall maintain records with the following information for each controlled substance:

(A) The name of the substance;
(B) Each finished form (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter) and the number of units or volume of finished form in each commercial container (for example, 100 tablet bottle or three milliliter (3 ml) vial);
(C) The number of commercial containers of each such finished form received from other persons, including the date and number of containers in each receipt and the name, address and registration number of the person from whom the containers were received;
(D) The number of units or volume of the finished form dispensed including the name and address of the person to whom it was dispensed, the date of dispensing, the number of units or volume dispensed and the written or typewritten name or initials of the individual who dispensed or administered the substance;
(E) The number of units or volume of the finished forms, commercial containers, or both, disposed of in any other manner by the registrant, including the date and manner of disposal and the quantity of the substance in finished form dispensed.

(4) Records for Exporters. Each registered exporter shall maintain records with the following information for each controlled substance:

(A) The name of the substance;
(B) The quantity (or number of units or volume in finished form) received from other persons, including the date and the quantity or number of units or volume of each receipt and the name, address and registration number of each person from whom the substance was received;
(C) The quantity (or number of units or volume in finished form) exported, including the date, quantity (or number of units or volume) and the export permit or declaration number for each exportation, but excluding all quantities (and numbers of units and volume) manufactured by an exporter under a registration as a manufacture, which quantities (and numbers of units and volumes) are to be recorded;
(D) The quantity disposed of in any other manner by the registrant including the date and manner of disposal and the quantity disposed.


19 CSR 30-1.048 Records for Practitioners and Researchers

PURPOSE: This rule sets requirements for record keeping for individual practitioners and researchers. It also sets requirements for the use of facsimile and electronic computer transmission of controlled substance prescriptions.

(1) Each individual practitioner, institutional practitioner and pharmacy shall maintain records with the following information for each controlled substance received, maintained, dispensed or disposed:

(A) The name of the substance;

(B) Each finished form (for example, ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per fluid ounce or milliliter) and the number of units or volume of finished form in each commercial container (for example, 100 tablet bottle or three milliliter (3 ml) vial);

(C) The number of commercial containers of each such finished form received from other persons, including the date of and number of containers in each receipt and the name, address and registration number of the person from whom the containers were received;

(D) The number of units or volume of the finished form dispensed including the name and address of the person to whom it was dispensed, the date of dispensing, the number of units or volume dispensed and the written or typewritten name or initials of the individual who dispensed or administered the substance;

(E) The number of units or volume of the finished forms, commercial containers, or both, disposed of in any other manner by the registrant, including the date and manner of disposal and the quantity of the substance in finished form dispensed.

(2) Each individual practitioner shall maintain a record of the date, full name and address of the patient, the drug name, strength, dosage form and quantity for all controlled substances prescribed or administered. This record may be maintained in the patient’s medical record. When the controlled substance record is maintained in the patient’s medical record and the practitioner is not the custodian of the medical record, the practitioner shall make the controlled substance record available as required in 19 CSR 30-1.041 and 19 CSR 30-1.044.

(3) Individual practitioners shall maintain the records listed in subsections (1)(A)–(E) of this rule separately from patient medical records.

(4) A registrant who transfers a controlled substance to or receives a controlled substance from another registrant shall maintain a written record of the transfer which contains the following information: the date of transfer, drug name, strength, dosage form, quantity, name, address and registration number of the transferring registrant and the name, address and registration number of the receiving registrant.

(5) Drug Enforcement Administration official order forms shall be used for transfers of Schedule II controlled substances.

(6) A prescription may not be issued for an individual practitioner to obtain controlled substances...
Chapter 1—Controlled Substances

19 CSR 30-1.050 Records for Chemical Analysts

PURPOSE: This rule sets requirements for record keeping for chemical analyst registrants.

(1) Each person registered to conduct chemical analysis with controlled substances shall maintain records with the following information (to the extent known and reasonably ascertainable by him/her) for each controlled substance:

(A) The name of the substance;

(B) The form(s) in which the substance is received, imported, or manufactured by the registrant (for example, powder, granulation, tablet, capsule or solution) and the concentration of the substance in that form (for example, Chemically Pure (CP), United States Pharmacopeia (USP), National Formulary (NF), ten milligram (10 mg) tablet or ten milligram (10 mg) concentration per milliliter);

(C) The total number of the forms received, imported, or manufactured (for example 100 tablets, 30 one milliliter (1 ml) vials or ten grams (10 g) powder), including the date and quantity of each receipt, importation or manufacture and the name, address and registration number, if any, of the person from whom the substance was received; and

(D) The quantity distributed, exported or destroyed in any manner by the registrant (except quantities used in chemical analysis or other laboratory work), including the date and manner of distribution, exportation or destruction and the name, address and registration number, if any, of each person to whom the substance was distributed or exported.

(2) Order forms, import and export permits, import invoices and export declarations relating to controlled substances shall be maintained separately from all other records of the registrant.

(3) Records of controlled substances used in chemical analysis or other laboratory work are not required.

(4) Records relating to known or suspected controlled substances received as samples for analysis are not required under section (1) of this rule.


19 CSR 30-1.052 Records for Long-Term Care Facilities (LTCF)

PURPOSE: This rule sets requirements for record keeping by long-term care facility registrants.

(1) Long-term care facilities (LTCFs) and their suppliers shall maintain written records of transfers of controlled substances from the supplier to the LTCF emergency kit.

(2) The records shall include the date of transfer, the name of each controlled substance, the strength, dosage form and quantity; the name, address and controlled substance registration number of the supplier and the name, address and controlled substance registration number of the LTCF. Federal Drug Enforcement Administration (DEA) official order forms shall not be used to record transfers of controlled substances to LTCF emergency kits.

(3) No physician’s order or prescription shall be used for initial stocking or replacement of controlled substances in the emergency kit. Controlled substances contained in the kit shall be obtained from a pharmacy, hospital or practitioner who holds a controlled substances registration.

(4) The administration and medical staff of the LTCF, in conjunction with the primary supplier, shall designate in written protocols and procedures who may have access to the emergency kit, who may administer controlled substances from the emergency kit and under what circumstances and a list of the controlled substances it intends to maintain in the emergency kit. These protocols and procedures shall be subject to review and approval by the Department of Health. Only those individuals designated in the LTCF’s written policies and procedures shall have access to or administer controlled substances from the emergency kit.
19 CSR 30-1.060 Determining Lawful Prescribing, Dispensing and Administering of Controlled Substances

PURPOSE: This rule defines the statutory and regulatory basis for determining what is lawful prescribing, dispensing and administering of controlled substances.

When determining if controlled substances are being lawfully prescribed, dispensed and administered by practitioners, the Department of Health shall enforce Chapter 195, RSMo, the Department of Health rules in 19 CSR 30 pertaining to controlled substances, and the federal Controlled Substances Act 21 U.S.C. 801–966, and its regulations, 21 CFR 1300–1399. In determining lawful prescribing, dispensing and administering of controlled substances, the Department of Health also shall consider the provisions of Chapters 330, 332, 334, 335, 336, 338 and 340, RSMo, the rules in 4 CSR 110, 4 CSR 150, 4 CSR 200, 4 CSR 210, 4 CSR 220, 4 CSR 230 and 4 CSR 270, and protocols relating to the respective practitioners established and on file at the respective licensing boards.


19 CSR 30-1.062 Transmission of Prescriptions

PURPOSE: This rule sets requirements governing the transmission of prescription information.

(1) Prescriptions in Schedule II. A pharmacist may dispense a controlled substance in Schedule II only under a written prescription signed by the practitioner, except as provided in section 195.060.3, RSMo. A prescription for a Schedule II controlled substance may be transmitted from the prescribing practitioner to a pharmacy by facsimile equipment or electronic computer transmission, provided the original written, signed prescription is presented to the pharmacist for review prior to the actual dispensing of the controlled substance, except that—

(A) A prescription written for a Schedule II narcotic substance to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may be transmitted by the practitioner or the practitioner’s agent to the pharmacy by facsimile or by electronic computer transmission. The facsimile or the computer transmission which has been reduced to writing shall serve as and shall be maintained in the same manner as an original written prescription.

(B) A prescription written for a Schedule II substance for a resident of a long-term care facility may be transmitted by the practitioner or the practitioner’s agent to the pharmacy by facsimile or by electronic computer transmission. The facsimile or the computer transmission which has been reduced to writing shall serve as and shall be maintained in the same manner as an original written prescription.

(C) A prescription written for a Schedule II substance for a patient of a hospice may be transmitted by the practitioner or the practitioner’s agent to the pharmacy by facsimile or by electronic computer transmission. The practitioner or the practitioner’s agent shall note on the prescription that the patient is a hospice patient. The facsimile or the computer transmission which has been reduced to writing shall serve as and shall be maintained in the same manner as an original written prescription.

(2) Prescriptions in Schedule III, IV or V. A pharmacist may dispense directly a controlled substance in Schedule III, IV or V only under a written prescription signed by a practitioner or a facsimile of a written, signed prescription transmitted by the practitioner or his/her authorized agent or under an oral prescription made by an individual practitioner whether communicated by the practitioner or his/her authorized agent or a prescription transmitted by electronic computer transmission by the authorizing practitioner or the practitioner’s agent to the pharmacy. All oral prescriptions and prescriptions transmitted by electronic computer transmission shall be promptly reduced to writing by the pharmacist containing all information required in section 195.060, RSMo, except for the signature of the practitioner.

(3) Written Prescriptions. All written controlled substance prescriptions shall be signed by the prescribing practitioner on the date prescribed. No controlled substance prescription shall be signed prior to the actual date it is issued.


19 CSR 30-1.064 Partial Filling of Schedule II Prescriptions

PURPOSE: This rule sets requirements for the partial filling of Schedule II prescriptions.

(1) The partial filling of a prescription for a controlled substance listed in Schedule II is permissible, if the pharmacist is unable to supply the full quantity called for in a written or emergency oral prescription and s/he makes a notation of the quantity supplied on the face of the written prescription (or written record of the emergency oral prescription). The remaining portion of the prescription may be filled within 72 hours of the first partial filling; however, if the remaining portion is not or cannot be filled within the 72-hour period, the pharmacist shall so notify the prescribing individual practitioner. No further quantity may be supplied beyond 72 hours without a new prescription.

(2) A prescription for a Schedule II controlled substance written for a patient in a long-term care facility (LTCF) or for a patient with a medical diagnosis documenting a terminal illness may be filled in partial quantities to include individual dosage units. If there is any question whether a patient may be classified as having a terminal illness, the pharmacist must contact the practitioner prior to partially filling the prescription. Both the pharmacist and the prescribing practitioner have a corresponding responsibility to assure that the controlled substance is for a terminally ill patient. The pharmacist must record on the prescription whether the patient is “terminally ill” or an “LTCF patient.” A prescription that is partially filled and does not contain the notation “terminally ill” or “LTCF patient” shall be deemed to have been filled in violation of Chapter 195, RSMo. For
19 CSR 30-1.066 Dispensing by Individual Practitioners

PURPOSE: This rule sets requirements for individual practitioners who dispense controlled substances.

(1) An individual practitioner who dispenses controlled substances shall—

(A) Provide direct supervision to employees or agents who assist in the administering or dispensing of controlled substances. Controlled substances shall not be dispensed from an individual practitioner’s inventory unless a practitioner is physically in the registered location except pursuant to the provisions of section (2) of this rule;

(B) Package all controlled substances dispensed from an individual practitioner’s inventory in compliance with the Poison Prevention Packaging Act of 1970, 15 U.S.C. 1471–1476;

(C) Permanently affix a label to the exterior of the drug container which includes: the date, the name and address of the dispensing pharmacist, the name of the patient, directions for use, and the exact name and strength of the drug dispensed for all controlled substances dispensed;

(D) Dispense only to individuals with whom the practitioner has established and documented a practitioner/patient relationship. An individual practitioner shall not dispense under the order of another practitioner not practicing at that location.

(2) Controlled substances may be administered or dispensed from an individual practitioner’s inventory by an authorized employee or agent when the practitioner is not present at the registered location when—

(A) The administration or dispensing is authorized by the individual practitioner under a written agreement pursuant to an arrangement established and implemented in accordance with Missouri statutes;

(B) The person who administers or dispenses the controlled substance is authorized by statute to administer or dispense controlled substances;

(C) The person who administers or dispenses the controlled substance is registered with the Department of Health to administer or dispense controlled substances;

(D) The person who administers or dispenses the controlled substance does so in compliance with all provisions of Chapter 195, RSMo and subsections (1)(B), (C) and (D) of this rule.

19 CSR 30-1.068 Administering In Emergency Rooms

PURPOSE: This rule sets requirements for administering controlled substances in hospital emergency rooms.

(1) Controlled substances may be administered to a hospital emergency room patient under a verbal order of a registered practitioner who is not physically present if—

(A) The order is for a legitimate medical purpose and the practitioner who orders the administration of a controlled substance is acting in the usual course of his/her medical practice, after sufficient examination and establishment of a practitioner/patient relationship;

(B) The practitioner who orders the administration of a controlled substance is a medical staff member of the hospital;

(C) The administration of a controlled substance is documented in a formal medical record for the patient;

(D) The patient is assessed in the hospital by a practitioner, when available, or a registered nurse. If the patient is not assessed by a practitioner in the hospital, a registered nurse shall assess the patient and confirm and document in the patient’s medical record the existence of a preestablished practitioner/patient relationship with the practitioner who ordered administration of a controlled substance;

(E) The order is written in the patient’s medical record and is authenticated by the ordering practitioner within a time frame and manner as defined by the medical staff in cooperation with nursing and administration. This policy shall be included in the hospital’s written policies and procedures.

19 CSR 30-1.070 Emergency Dispensing of Schedule II Substances

PURPOSE: This rule provides for the prescribing and dispensing of Schedule II drugs in an emergency situation.

(1) In the case of a bona fide emergency situation, as defined by the Department of Health, a pharmacist may dispense a Schedule II controlled substance upon receiving oral authorization of a prescribing practitioner; provided, that—

(A) The quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. Prescribing or dispensing beyond the emergency period must be pursuant to a written prescription;

(B) The prescription immediately shall be reduced to writing by the pharmacist and shall contain all information, except for the prescribing practitioner’s signature;

(C) If the prescribing practitioner is not known to the pharmacist, s/he must make reasonable effort to determine that the oral authorization came from a practitioner, by verifying his/her phone number against that listed in the directory and other good faith efforts to insure his/her identity;

(D) Within seven days after authorizing an emergency oral prescription, the prescribing practitioner must cause a written prescription for the emergency quantity prescribed to be delivered to the dispensing pharmacist. The prescription shall have written on its face authorization for emergency dispensing. The written prescription may be delivered to the pharmacist in person or by mail, but if delivered by mail it must be postmarked within the seven-day period. Upon receipt, the dispensing pharmacist shall attach this prescription to the oral emergency prescription which had been filled.
purposes, the actual cash transaction, credit transaction or delivery may be completed by
a nonpharmacist);

(B) Not more than two hundred forty cubic centimeters (120 cc) four ounces (4 oz.) of any
other controlled substance nor more than 48 dosage units of any controlled substance containing
opium, nor more than one hundred twenty cubic centimeters (120 cc) four ounces (4 oz.) of any
other controlled substance nor more than 48 dosage units of any controlled substance containing
opium, nor more than 24 dosage units of any other controlled substance may be dispensed at retail
to a purchaser (the name or initials of the pharmacist who dispensed the substance to the purchaser
shall be written in a book kept by the pharmacist). The book shall contain the name and address
of the purchaser, the date of each purchase and the name and quantity of controlled substance
purchased, the date of each purchase and the name or initials of the pharmacist who dispensed
the substance to the purchaser (the book shall be maintained in accordance with record
keeping requirements);

(F) A prescription is not required for distribution or dispensing of the substance pursuant
to any federal, state or local law.


19 CSR 30-1.076 Emergency Distribution by a Pharmacy

PURPOSE: This rule provides for dispensing of controlled substances by a pharmacy in
emergency situations.

(1) An emergency means a situation where a quantity of a controlled substance must be
dispensed by a pharmacy to a patient who does not have an alternative source for that
substance reasonably available to him/her and the pharmacy cannot obtain that substance
through its normal distribution channels within the time required to meet the immediate
needs of the patient for that substance. In the event of an emergency, a pharmacy may
communicate with another pharmacy in order for that pharmacy to dispense the substance;
provided, that—

(A) The amount distributed does not exceed the amount required by the second
pharmacy to order that substance for immediate dispensing;

(B) The distribution is recorded as being dispensed by the first pharmacy and the
second pharmacy records the transaction as being received. Each pharmacy will retain a signed
receipt of the distribution;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;

(C) The second pharmacy is registered to
dispenser to the same purchaser in any
given 48-hour period;
19 CSR 30-1.078 Disposing of Unwanted Controlled Substances

PURPOSE: This rule establishes procedures for disposing of unwanted controlled substances.

1. Single units of controlled substances which are contaminated by patient body fluids and are not an infectious hazard, or have been removed from their original or security packaging, or are partially used, or are otherwise rendered unsuitable for patient use shall be destroyed by a pharmacist in the presence of another hospital employee or held for later destruction;

2. All other controlled substances which are not patient contaminated but which are to be disposed of shall be returned to the pharmacy for disposal;

3. The remaining contents of opened glass ampules of controlled substances shall be destroyed by a nurse, pharmacist or physician in the presence of another hospital employee;

4. Single units of single dose packages of controlled substances which are contaminated other than by patient body fluids and are not an infectious hazard, or have been removed from their original or security packaging, or are partially used, or are otherwise rendered unsuitable for patient use shall be destroyed by a nurse, pharmacist or physician in the presence of another hospital employee or returned to the pharmacy for destruction;

5. The following shall be entered in the controlled substance administration record or a separate controlled substance destruction record when the controlled substance is destroyed in the patient care area: the date and hour of destruction, the drug name and strength, the amount destroyed, the reason for destruction and the patient’s name and room number. The nurse, pharmacist or physician and the witnessing hospital employee shall sign the entry. The drug shall be destroyed so that it is beyond reclamation. The controlled substance administration or destruction records are to be retained for two years and available for inspection by Department of Health investigators;

6. All other controlled substances which are not patient-contaminated but are to be disposed of shall be placed in a suitable container for storage and disposed of as described in section (1) of this rule.
